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Abstract
Inflammation is a major risk factor for many types of cancer, and the physiological processes
involved in inflammation can contribute to many aspects of cancer development. Inflammation
entails reprogramming of cell behaviors that resemble cancer, such as increased proliferation and
signals for survival and migration, and it also entails production of reactive chemical species,
which can damage DNA to promote genetic instability, another hallmark of cancer. While much
research has been dedicated to studying the relationships between inflammation and cancer, it
has been difficult to distinguish the relative contributions of modified cell behavior and de novo
mutagenesis to the development of cancer. Furthermore, few studies have addressed the role(s)
inflammation plays in cancer initiation versus promotion. Here, we utilized a transgenic mouse
for detecting mutations in a variety of models of inflammation to parse the mechanisms by which
inflammation contributes to mutations and cancer.
The RaDR mouse, developed in the Engelward lab, contains a ubiquitously expressed transgene
that enables detection of sequence rearrangement mutations following aberrant homologous
recombination (HR). These mice also contain the Gpt-A transgene for detecting point mutations
and deletions, enabling unprecedented breadth and depth of possible mutation analyses in a
single tissue. Our studies began by querying whether elements that regulate inflammation protect
against mutagenesis in RaDR animals. We then studied RaDR mutagenesis in several models of
intestinal inflammation and cancer. Together, these experiments showed that inflammation does
not significantly induce de novo sequence rearrangement mutations, but it greatly increases the
overall burden of mutant cells in a tissue as a result of heightened proliferation and clonal
expansion.
We also used the RaDR mouse model to expand upon studies of DNA repair pathway balance.
DNA damage is addressed by a network of pathways, each designed to identify and repair
specific types of lesions. One of the most important repair pathways for DNA damage caused by
inflammation is the Base Excision Repair (BER) pathway, and we have previously found that
BER intermediates can increase the frequency of mutagenic HR. Here, we expand upon that
6
information, showing that acceleration of the BER pathway by increased expression of an
initiating enzyme does not increase sequence rearrangement mutations, provided the downstream
pathway can be resolved efficiently.
Together, the studies described herein demonstrate that inflammation is unlikely to initiate
cancer via sequence rearrangement mutations, but inflammation is a strong promoter of cancer in
part through increased clonal expansion of mutant cells.
Thesis Supervisor: Bevin P. Engelward
Title: Professor of Biological Engineering
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Chapter 1
Introduction
As early as 1863, Virchow recognized the inextricable connections between the immune system
and cancer development. Virchow's prediction that cancer arises at sites of "lymphoreticular
infiltrate" has been confirmed many times over, as pancreatitis, hepatitis, colitis, and other
chronic inflammatory diseases are now known to be major risk factors for cancer in those tissues
[1-6]. In fact, chronic inflammation is often necessary for tumor development [1, 7-9]. The
inflammatory environment promotes cellular proliferation and survival, degradation and
remodeling of the extracellular matrix, and weakening of vascular barriers to facilitate immune
cell migration, all of which enable cancer growth [10, 11]. Inflammation is so pro-tumorigenic
that tumors can even generate their own inflammatory microenvironment to facilitate growth [7,
12]. Accordingly, mitigating inflammation is often an effective strategy for slowing or even
preventing neoplasia [3, 13, 14]. There are many excellent reviews on a wide range of
connections between inflammation and cancer [7, 10, 12, 15]. Here, we will focus on how
inflammation and DNA damage contribute to each other as well as to the development of cancer.
Many departures from normal behavior that cancer cells exhibit, such as unchecked
proliferation and aberrant migration, can be traced to mutations in DNA that accumulate over
time. Mutations generally arise from damaged DNA, and inflammation can cause a great deal of
DNA damage. A central component of inflammation is the production of reactive chemicals
designed to destroy pathogens, and while these chemicals are essential for protecting the body
from infection, they can damage host biomolecules as well, including DNA. Efficient repair of
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DNA damage is crucial to prevent mutations in the genetic code. As such, several DNA repair
mechanisms have evolved to address the many types of DNA damage. However, DNA repair can
be fallible or unable to handle excessive damage, allowing mutations to occur. Since cancer
develops from accumulated mutations, it logically follows that DNA damage from inflammation
contributes to cancer development by increasing mutagenesis.
It is broadly appreciated that genomic instability is a hallmark of cancer [16-19]. The
human haploid genome contains 3.2x 109 base pairs, and the spontaneous rate of mutation in
normal human cells is estimated to be on the order of 1-1Ox10-10 nucleotides/cell/division [20-
22]. Several driver mutations are required within the same cell lineage for it to become
malignant, and although the number of necessary mutations has not been defined and likely
depends on the type of cancer, the minimum number is around three [23, 24]. The there are
approximately 3x 10 cells in the human body, and the average human lifespan comprises 1016
cell divisions (BNIDs 100379, 108562)[25]. According to Loeb, the probability of any one cell
acquiring three mutations is approximated by (1x10'10 spontaneous mutations/cell/division) 3(1016
cell divisions/lifetime)= 10-4 potential cancer cells/lifetime [21]. In other words, the prevalence
of cancer in the population should be less than one in a trillion people, whereas the actual
lifetime probability of developing cancer is ~38.5% [26]. Furthermore, tumor cells contain
dozens, sometimes thousands, of mutations. Thus, it is clear that factors such as genetics,
environmental exposures, and physiology are required to increase mutation frequency beyond the
normal rate to promote cancer, a quality known as a mutator phenotype [21].
Inflammation and genomic instability have a complex relationship (a highly simplified
roadmap is shown in Figure 1-1, which will become more detailed throughout this review).
Inflammation contributes to mutagenesis through production of reactive oxygen and nitrogen
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species (RONS) that can damage DNA, but DNA damage can also exacerbate inflammation.
This positive feedback loop is carefully regulated by a network of DNA repair pathways,
transcription factors, and cellular signals. Due to the intricacies linking inflammation, DNA
damage, and DNA repair, these processes can easily become dysregulated and lead to cancer.
1.1 Inflammation Leads to DNA Damage
The majority of inflammation-induced DNA damage is caused by reactive oxygen and nitrogen
species (RONS), which are evolved by immune cells to destroy pathogens, but which can also
damage self-biomolecules. One pleiotropic RONS chemical is nitric oxide (NO), which is an
essential signaling molecule with functions in the cardiovascular, nervous and immune systems
[27, 28]. For most of these processes, the concentration of NO is below 400 nM [29]. During
inflammation, however, innate immune cells produce NO at high levels (approaching pM [30,
31]), as well as superoxide and numerous enzymes, leading to a cascade of chemical reactions
that produce a range of RONS (Fig 1-2). These reactive species include radicals (e.g., superoxide
O*2 , hydroxyl 'OH, and nitrogen dioxide N0 2 '), anions (e.g., peroxynitrite ONOO, and
nitrosoperoxycarbonate ONOOC0 2 7), anhydrides (e.g., nitrous anhydride N203), hypohalous
acids (e.g., hypochlorous acid HOCl and hypobromous acid HOBr) and hydrogen peroxide
(H2 02 ). In addition to the RONS produced by immune cells, pro-inflammatory cytokines can
stimulate intracellular RONS production [32-34]. For excellent reviews on RONS and their
chemistry, please see [35, 36].
To understand the mutagenic consequences of inflammation, one must first recognize the
chemical modifications to DNA and the mechanisms for repair of those lesions. We begin with a
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discussion of the DNA damage produced from RONS, including nucleobase oxidation,
deamination, halogenation, and alkylation, as well as strand breaks of the phosphodiester
backbone. Subsequent sections will review the major repair pathways for these types of damage;
the mechanisms that balance DNA damage, DNA repair, and inflammation; and the implications
for carcinogenesis.
1.1.1 Oxidation
Many RONS are potent oxidizing agents and can create several kinds of damage to DNA. While
there are many potential products of DNA oxidation [37], guanine is the most easily oxidized
DNA base [36] and is therefore the primary target for reaction with nucleophilic RONS and the
focus of this section. Primary oxidation of guanine by RONS produces 8-oxo-guanine (8oxoG,
which is mutagenic) and 8-nitro-guanine (which is unstable and quickly becomes an abasic site)
(Fig 1-3). 8oxoG in the normal anti conformation pairs with cytosine, but rotation of the
glycosidic bond to the syn position allows pairing with adenine (Fig 1-3) [38]; thus, 8oxoG can
lead to G4T transversions [38-40]. The potential for 8oxoG to cause this mutation depends on
the polymerase that encounters it, as will be described in later sections [40-42].
8oxoG is -1000 times more prone to oxidation than its parent guanine, leading to
production of several more stable and mutagenic secondary products. These include
spiroiminodihydantoin (Sp), guanidinohydantoin (Gh), oxazolone (Oz), oxaluric acid (0a), and
cyanuric acid (Ca) (see Fig 1-3 for examples). Oz, Oa and Ca have been shown to produce G+T
transversions with much higher potency than the parent 8oxoG [43]. Gh primarily leads to G-C
mutations, and Sp causes both G+T and G4C mutations, both with frequencies at least an order
of magnitude higher than that of 8oxoG [44]. While Gh is relatively easily bypassed (albeit
21
mutagenically), Sp blocks replication [44] and leads to strand slippage, producing broken
replication forks and single base pair deletions in addition to transversions [45, 46]. Until
recently, mutagenicity of the secondary oxidation products of 8oxoG had been demonstrated
almost exclusively in E. coli [43, 44, 47, 48], but studies with mammalian systems in the past
decade have yielded similar results [46, 48, 49], suggesting shared mechanisms between species.
In addition to secondary oxidation, 8oxoG can be reduced, opening the imidazole ring to
form a 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG). FapyG produces G-T
transversions in mammalian cells [50], and some studies suggest it may be more mutagenic than
the parent 8oxoG [51].
1.1.2. Deamination
In addition to oxidation, nitrosative RONS can deaminate DNA bases. Deamination products are
particularly mutagenic because the chemistry occurs on the functional groups that determine
hydrogen bonding, altering the pattern of H-bond donors and acceptors and leading to base
mispairing. The chemical primarily responsible for base deamination is thought to be nitrous
anhydride [35], generating the products from canonical bases shown in Figure 1-4 (note that Hx
is dl in DNA). Indeed, in vitro exposure of DNA to nitrosative RONS produces high amounts of
X, Hx and U lesions [52, 53].
Deamination of cytosine or its methylated form 5meC changes the base into uracil or
thymine, respectively, causing C-T transitions. Recently it has been shown that deamination of
adenine to produce hypoxanthine (Hx) can cause either A-+G transitions or deletions, depending
on the cell type and whether the lesion is on the leading or lagging strand [54]. Finally, guanine
deamination to xanthine (X) primarily causes G-A transitions [53], possibly by tautomerization
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of X to an enol form that can pair with T. Nitrosative deamination of G or A at the N7 position
can also cause depurination to form an abasic site [55].
Interestingly, while U, Hx and X occur in at high levels in in vitro studies [52], these
deamination products are rarely observed in cells stimulated with physiological levels of RONS
[55]. One possibility for the low cellular levels of these lesions is that repair is very rapid, which
is consistent with evolutionary selection for efficient repair of highly mutagenic lesions. Overall,
while the chemistry of inflammation probably produces a great deal of deamination, these lesions
are rarely observed in vivo, possibly due to rapid repair to counterbalance their potent
mutagenicity.
1.1.3. Halogenation
Inflammatory chemicals are not limited to oxygen and nitrogen species. Neutrophils secrete the
enzyme myeloperoxidase to produce hypochlorous acid (HOCl) [56-58], and eosinophils secrete
eosinophil peroxidase to produce hypobromous acid (HOBr) [59, 60] (Fig 1-2). These
hypohalous acids readily react with DNA to form the adducts shown in Figure 1-5. Interestingly,
the most abundant halogenated nucleobase, 5-chlorocytosine (5ClC) [61, 62], accumulates to a
greater degree than oxidative, deamination or LPO (described below) DNA lesions [48, 63]. Due
to its significant and persistent accumulation, perhaps a result of inefficient repair, 5ClC has been
designated a biomarker for chronic inflammation [48, 63, 64].
The mutagenicity of halogenated DNA has only recently been demonstrated.
Halogenation had previously been shown to impact epigenetic modifications [65], but now 5ClC
has been shown to cause C->T transitions [64]. These mutations are frequently observed in
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tissues under inflammatory stress as well as in inflammation-associated cancers [63, 64, 66],
further supporting the designation of 5ClC as a pertinent biomarker for inflammation.
1.1.4. Lipid Peroxidation-Derived Adducts
Oxidative stress can directly damage DNA, as described above, but it can also cause indirect
damage by creating reactive species from other biomolecules. Specifically, when RONS
encounter polyunsaturated fatty acids, they cause lipid peroxidation (LPO) to generate
electrophilic, DNA-reactive aldehyde species. The best-studied of these aldehyde species are 4-
hydroxy-2-nonenal (HNE), malondialdehyde (MDA), acrolein, and crotonaldehyde [67], of
which HNE and MDA have been directly implicated in carcinogenesis [68]. The resulting LPO-
induced DNA adducts are exocyclic additions of two (F, etheno-) or three (P, propano-) carbons
onto a base [67, 69, 70]. Examples of etheno adducts are shown in Figure 1-6. Many studies have
demonstrated significant accumulation of etheno adducts as a result of inflammation [48, 69, 71-
73].
The most abundant etheno adduct found in DNA is N2 ,3-FG [74, 75]. N2,3-gG is a potent
inducer of G+A transitions, and its isomer 1,N2-cG causes G-)>T and G+C transversions [74,
76, 77]. 1,N6-cA causes primarily A->G and A-T mutations [78, 79], and 3,NA 4-C potently
induces C4A and C-*T mutations [70, 80]. All etheno lesions can block replication to some
extent [74, 77, 80], which can lead to larger-scale mutations (discussed below).
1.1.5. Single Strand Breaks (SSBs)
While lesions on nucleobases are an important source of mutations, breakage of the DNA
backbone is a far greater threat to genomic integrity. Strand breaks potentiate large-scale
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mutations, such as deletions, insertions, and translocations, and they can also cause stress
signaling, cell cycle arrest, and cytotoxicity if not efficiently repaired [81-85]. During
inflammation, single strand breaks (SSBs) can arise from direct reaction with RONS: for
example, radicals can hydrolyze the phosphodiester backbone, and peroxynitrite produces single
strand breaks and abasic sites [86]. SSBs also occur naturally as intermediates of some DNA
repair pathways.
1.1.6. Double Strand Breaks (DSBs)
Double strand breaks (DSBs) also arise from a variety of sources. Some enzymes, such as
endonucleases and topoisomerases, cut the backbone to produce DSBs [87, 88]. SSBs can also
potentiate DSBs: for example, two nearby opposed SSBs may reduce the structural integrity of
the DNA duplex, and the strand will break apart (Fig 1-7A). Additionally, if a polymerase
encounters a SSB during replication, the replication machinery cannot synthesize past the gap,
and the replication fork collapses, leaving a one-ended DSB (Fig 1-7B). Similarly, replication-
blocking lesions such as cA, cC, and Sp can cause DSBs, possibly because the stress of a
replication fork encountering a lesion that cannot be bypassed causes breakage of the backbone,
though the exact mechanism(s) for this breakage remains unclear [89, 90]. While both DSBs and
SSBs can be mutagenic, DSBs are one of the most deleterious types of DNA damage [91].
Strand breaks potentiate large-scale mutations, including insertions, deletions, translocations, and
sequence rearrangements [92-95].
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1.2 Repair of Inflammation-Induced DNA Lesions
In order to minimize mutations, multiple mechanisms have evolved to address different types of
DNA damage. The simplest way to prevent mutations is through accurate replication of DNA.
Polymerases read the template strand and select the correct nucleotide based on the template
base's shape and hydrogen bonding pattern to extend the strand being synthesized. When the
hydrogen bonding of a base is altered (e.g., by deamination) or blocked (e.g., by etheno adducts),
the cell first attempts to synthesize past the lesion (translesion synthesis, or TLS), often using a
low-fidelity polymerase, which is only sometimes accurate [51, 96, 97]. However, some lesions
cannot be efficiently bypassed by TLS, causing the replication fork to stall [98]. Several
mechanisms are capable of restoring stalled replication forks, some of which leave the lesion in
place [89], but inefficient fork restoration can cause strand breakage as described above.
Supplementary to polymerase selectivity and proofreading, several DNA repair pathways
have evolved to correct lesions before and during replication. The rate of incorrect base
incorporation (point mutation) for replicative polymerases is on the order of 10-6 to 10-8
nucleotides [99], and with 3.2x10 9 bases in the genome, at least ten point mutations would occur
with every cell division. DNA repair processes reduce point mutation frequency to 1010 [21] and
also protect against large-scale mutations such as insertions, deletions and rearrangements. DNA
repair is of particular importance during inflammation because of (i) the large amount of reactive
chemicals produced and (ii) the stimulation of cellular proliferation to regenerate damaged
tissue. The combination of damage and cell division synergistically increase mutagenesis [100],
and persistent DNA damage signals cell death [83, 101] which may be why deficiencies or
imbalance in DNA repair proteins can greatly sensitize animals to inflammation [72, 102-106].
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Most DNA damage from inflammation is addressed by the Direct Reversal (DR), Base
Excision Repair (BER), and Homologous Recombination (HR) pathways. Here we will briefly
describe each pathway and discuss their interactions for robust repair of inflammation-derived
damage.
1.2.1. Direct Reversal (DR)
Some DNA alkyl adducts can be directly removed from the base in a process called Direct
Reversal, leaving the original base intact. For example, the 06-methylguanine DNA
methyltransferase (MGMT) protein repairs 06-methylguanine by transferring the methyl group
to a cysteine residue in its active site [107]. The other mammalian DR enzymes belong to the
ALKBH family, which utilize oxygen, Fe2 and a-ketoglutarate as co-factors for oxidative
dealkylation, releasing the alkyl lesion as an aldehyde and restoring the original base [108, 109].
Importantly, ALKBH enzymes can repair etheno adducts, and therefore supplement BER during
inflammation [110].
1.2.2. Base Excision Repair (BER)
In general, Base Excision Repair deals with single-base lesions that do not significantly distort
the DNA helix; since this encompasses most inflammation-derived lesions, BER is the primary
pathway responsible for DNA repair during inflammation. The first step of BER is removal of
the damaged base by one of several DNA glycosylases. The second step is to nick the backbone,
which can be accomplished by some glycosylases, AP endonuclease-1 (APEl), or AP lyase. The
two ends of the single strand break must then be processed to produce a 3'OH (with APE I, Polp,
or PNKP) capable of extension and a 5'PO 4 (with Pol or PNKP) capable of ligation. The gap is
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filled in with Polp, and ligase seals the nick to complete the process. The elements of BER
downstream of the glycosylase can also contribute to repair of SSBs.
Each glycosylase has its own repertoire of substrates, and there is some redundancy in
substrate recognition to ensure a robust response. Some of the most important DNA glycosylases
for repairing damage from inflammation are 8-oxo-guanine glycosylase (OGGI), which removes
8oxoG and FapyG [111], and alkyladenine glycosylase (AAG, also known as MPG or ANPG),
which removes cA, 1,N2 -FG, Hx, and 8oxoG, among others [72, 112]. AAG also recognizes and
binds to PC, but it cannot excise the base, instead blocking replication and contributing to its
increased genotoxicity [80]. Damaged pyrimidines may be excised by pyrimidine-specific
glycosylases such as MBD4, UNG, TDG, and SMUG1 [112]. The enzyme MYH uniquely
protects against 8oxoG mutagenesis, because it specifically recognizes and excises A
misincorporated across from 8oxoG during replication [112]. Other BER glycosylases, such as
NTHL 1, NEIL 1, and NEIL2, can recognize a broad range of substrates, including FapyG,
hydantoin lesions, 8oxoG, and oxidized pyrimidines [46, 49, 105, 112, 113], providing robust
repair of single-base lesions.
Importantly, every intermediate of the BER pathway contains a potentially toxic lesion:
either an abasic site or some kind of strand break. Normally, the cell is able to complete BER
without toxicity, but this is not always the case. If there is a large amount of damage, there may
be simply too few of the molecules necessary for repair, leading to an accumulation of cytotoxic
lesions and subsequent apoptosis. Alternatively, if a replication fork encounters a BER
intermediate, the fork may break down, creating a DSB. Thus, while BER is essential for
repairing DNA damage during inflammation, this pathway can sometimes do more harm than
good by generating toxic intermediates.
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1.2.3. Double Strand Break Repair
Although DSBs generally arise as secondary lesions during inflammation (e.g., from replication
fork breakdown or nearby opposing SSBs) they are one of the most toxic types of DNA damage
[91, 93, 95, 114]. Here, we will briefly describe the two major pathways responsible for DSB
repair: Non-Homologous End Joining (NHEJ) and Homologous Recombination (HR).
NHEJ, the dominant repair mechanism in GI phase [115], functions by joining two DSB
ends with the Ku70/80 and DNA-PK complexes, and ligating the strands together. This process
occurs quickly but is very prone to error. For example, if the two DSB ends are from different
chromosomes, translocations occur. However, since DSBs are generally rare in GI, NHEJ
sufficiently preserves genomic integrity during this cell cycle phase.
Homologous Recombination repairs DSBs much more accurately than NHEJ, but it acts
more slowly and functions mainly during the S and G2 phases of the cell cycle [116]. Since the
risk for mutations is highest during replication, and since HR can rescue replication stress, this
pathway is of greater importance for inflammation-induced DNA damage. HR comprises
multiple subpathways with distinct mechanisms, so here we will provide a basic overview of the
major steps. HR begins by recognition of the DSB by CtIP and the MRN complex (consisting of
MRE1 1, NBS1 and RAD50). The 5' end of the DNA is resected by EXOl to leave a 3' overhang
of single stranded DNA, which is stabilized by the protein RPA. BRCA2 displaces the RPA,
replacing it with RAD5 1, and this 3' nucleoprotein filament searches nearby DNA for a
homologous sequence. Usually, the cell identifies the correct homologous sequence on the
nearby sister chromatid, which it invades and utilizes as a template to resume extension. There
are several sub-pathways of HR, but the most common is synthesis-dependent strand annealing
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(SDSA) (for more detailed descriptions and digital animations of HR mechanisms, please see
[117]). In SDSA, once enough DNA has been synthesized from the template, the overhang will
re-hybridize with its original strand, any remaining gaps will be filled, and DNA ligation
completes repair of the DSB. A highly simplified diagram of this pathway is shown in Figure 1-
8.
Since HR utilizes a homologous region of DNA as a template, this process is mostly
error-free as long as the cell identifies the correct sequence in the sister chromatid. However,
identification of homology in the homologous chromosome rather than the sister chromatid can
lead to loss of heterozygosity, a significant source of tumor suppressor inactivation [118, 119].
Furthermore, a significant portion of the genome has been identified as repetitive or repeat-
derived: nearly 10% of the genome consists of Alu repeats [120, 121], and a recent analysis
estimates 2/3 of the genome consists of repetitive elements [122]. Thus, there are many
opportunities for HR to identify a homologous sequence in the wrong location. Aberrant HR can
lead to translocations, deletions, insertions, or sequence rearrangements [94, 123-127]. Some of
the mechanisms for HR-derived mutations are illustrated in Figure 1-9. In addition to these large-
scale mutations, HR can also produce point mutations, because the polymerases that participate
in HR are often error-prone [98, 128-130].
As mentioned earlier, an important source of DSBs during inflammation is broken
replication forks, which generate only one DSB end (see Fig 1-7), and thus cannot be accurately
repaired by NHEJ. Therefore, lesions that cause replication fork breakdown (including
replication blocking lesions and SSBs) necessitate HR to restore the replication fork. Notably,
many of the intermediates of the BER pathway are SSBs, so if replication forks encounter these
breaks before BER is completed, HR may be initiated as well (Fig 1-8) [101, 131].
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1.3 Coordination of DNA Repair During Inflammation
Balance within and among pathways is crucial to genomic maintenance, so we will briefly
discuss how the pathways above coordinate for efficient repair.
1.3.1. Intra-Pathway Balance
The importance of balance within a repair pathway has been illustrated with studies of modulated
expression of BER proteins. Mice that contain a transgene for increased expression of Aag are
more sensitive to alkylation damage, whereas Aag-'- mice are more resistant [132]. This varied
sensitivity stems from the fact that BER intermediates (abasic sites and SSBs) are often more
toxic than the original lesion itself [133]. If the downstream repair proteins do not keep up with
glycosylase activity, intermediates accumulate and increase mutagenesis [134, 135] or signal cell
death [101]. Accordingly, elevated AAG expression in humans has been associated with lung
cancer risk [136, 137] and poor glioma prognosis [138].
1.3.2. Inter-Pathway Redundancy and Crosstalk
To account for potential imbalances or perturbations within repair pathways, there must also be
inter-pathway crosstalk, regulation and redundancy. The coordination of multiple DNA repair
pathways allows the network to address lesions quickly and compensate with other repair
mechanisms if the pathway is not resolved efficiently.
There is often redundancy within and between pathways so that multiple mechanisms can
correct the same lesion with equivalent efficacy. For example, supplementary to BER, Direct
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Reversal enzymes ALKBH2 and ALKBH3 can repair etheno lesions [72, 139], and nucleotide
excision repair (NER) can contribute to repair of the hydantoin lesions Sp and Gh [140, 141].
Redundancy between pathways is so important that mice lacking AAG, ALKBH2 and ALKBH3
are unable to survive even one episode of colonic inflammation [72].
In other cases, potentially redundant repair pathways are coordinated by cell cycle and
crosstalk between repair machinery. For example, NHEJ is the dominant mechanism to repair
DSBs during GO and GI phases of the cell cycle, but during replication, there is a much greater
chance that quick ligation of two DSBs will produce a mutation. Thus, NHEJ and HR activities
are regulated in part by cell cycle, and many of the proteins that recognize and bind DSBs
contribute to the choice of which pathway will complete repair [142-144].
Finally, repair processes may compensate for each other if the pathway that initiated
repair is not resolved efficiently. A particularly relevant example is that BER intermediates can
cause replication forks to break down, inducing HR for repair (Fig 1-8) [101, 145]. Kiraly et al.
showed that wild type levels of the BER protein AAG caused a greater accumulation of HR-
driven mutations compared to Aag' mice [131], indicating that even normal BER glycosylase
activity may result in aberrant DSB repair. Further, HR-driven mutations increased
synergistically when alkylation damage occurred during proliferation [100, 131]. When Aag
activity exceeds the capacity of downstream enzymes, as described above, accumulated BER
intermediates can cause stress signaling and apoptosis [132], or they can elicit responses from
other pathways, providing the opportunity for different types of mutations than the initial lesion
might have created [134, 135, 146]. Of course, there are many ways in which intermediates of
some pathways may be substrates for other pathways, but for the scope of this review we confine
this example to BER and HR [146].
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1.3.3. Fate of the Lesion
To illustrate the interplay among the repair mechanisms described here, let us consider cA (Fig
1-10), a LPO lesion that accumulates during inflammation. Starting from the top, efficient repair
of EA can be accomplished with either DR, which removes the etheno lesion and leaves the
undamaged base intact, or BER, which excises the entire base and re-synthesizes the DNA
properly. However, if FA is encountered during replication, mutagenic consequences can arise.
Translesion synthesis by an error-prone polymerase allows the putative development of a point
mutation; if the cA lesion is repaired following inaccurate TLS, the mutation will become fixed.
gA may also block some polymerases, causing the replication fork to stall. Stalled replication
forks can be restarted by several mechanisms [89], some of which leave the lesion intact, but
they may also break down to produce a one-ended DSB. Accurate restoration of the replication
fork by HR prevents mutagenesis, but aberrant HR or NHEJ causes large-scale mutations, such
as translocations, insertions and deletions (some examples are shown in Fig 1-9). DSBs are also
highly cytotoxic, so persistence or abundance of DSBs in the cell can signal for it to undergo
apoptosis [81, 91, 147]. Thus, a single rA lesion creates the opportunity for many types of
mutations through multiple repair pathways.
1.3.4. Transcriptional Regulation of DNA Repair During Inflammation
To cope with the barrage of DNA damage, inflammatory signaling includes upregulation of
DNA repair. Indeed, increasing severity of inflammation and precancerous lesions correlates
positively with DNA damage response indicators [146, 148, 149]. Elements of BER and HR are
promoted in inflammatory environments [148-1 53], and they have been shown to protect against
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inflammation-driven mutations [71, 154-156]. Here we will describe a few major examples of
transcription factors that moderate inflammation and their roles in promoting DNA repair.
One of the most important responses to oxidative stress is mediated by NRF2, a
transcription factor that regulates the expression of antioxidants and other cytoprotective
elements. Briefly, NRF2 is sequestered by KEAPI in the cytoplasm until stimulation by
oxidative stress, whereupon NRF2 translocates to the nucleus to bind antioxidant response
elements (AREs) in target gene promoters [157-159]. Target genes of NRF2 include glutathione
S-transferase (GST), NADPH quinone oxidoreductase 1 (NQO1) and superoxide dismutase
(SOD), known collectively as the adaptive response to oxidative and electrophilic damage [158,
160]. Neutralizing RONS to less reactive species protects DNA from much of the deleterious
chemistry described earlier.
In addition to antioxidant and metabolic enzymes, AREs have also recently been
identified in promoters of several DNA repair genes, including components of HR [150], NHEJ
[161], and BER [162]. Indeed, disruption of NRF2 activity has been shown to result in decreased
DNA repair activity [150] and increased levels of DNA adducts [163-165]. Thus, when present,
NRF2 helps to manage the self-damage from inflammation by increasing expression of genes
that neutralize oxidative stressors and promote DNA repair.
Several other transcriptional regulators of inflammation may also play roles in promoting
DNA repair. NFKB is a key transcription factor with roles in induction, propagation, and
eventual downregulation of inflammation, and DNA damage is one of many signals that can
activate it [166-168]. There is also evidence that NFKB enhances HR by stabilizing the CtIP-
BRCA1 complex [152]. Similarly, several members of the interferon regulatory factor (IRF)
transcription factor family promote DNA repair [169, 170]. For example, recognition of DSBs
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can induce IRF 1 signaling [169], and some of its target genes include elements of HR and BER
[151].
Overall, because inflammation produces a great deal of DNA damage, and the pathogenic
insults that cause inflammation also can cause DNA damage, transcriptional regulation of
inflammation includes increased DNA repair. Indeed, the only way an organism could evolve to
have a self-damaging physiological response like inflammation is to also efficiently repair the
damage it causes.
1.4 DNA Damage Promotes Inflammation in a Positive Feedback Loop
Many pathogens can cause DNA damage [153, 171-175], which may be why DNA damage can
induce inflammation. Furthermore, proteins that detect and respond to DNA damage can trigger
cell cycle arrest, apoptosis, senescence, and necrosis, of which the latter two can promote
inflammatory signaling [176-182]. Unfortunately, DNA damage and inflammation can therefore
create a positive feedback loop, which can be difficult to regulate. Additionally, response to
DNA damage in one cell can induce damage in nearby cells through extracellular signals and
epigenetic modifications [183-186]. The propagation of genomic instability to such "bystander"
cells, along with systemic inflammatory signals, may contribute to genotoxicity in off-target
tissues during inflammation [187-190].
There are many elements of the DNA damage response that promote inflammation. For
example, PARPI (poly(ADP-ribose) polymerase 1) detects and binds SSBs to recruit BER
machinery [191-195], and it has been closely linked to inflammation promotion. PARPI builds
branched polymers of ADP-ribose moieties out of NAD+ (called PARylation) at strand breaks to
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help recruit BER proteins and initiate repair. PARP1 is also capable of post-translational
PARylation of proteins to modify their activity, notably including the key inflammatory
regulator NFKB [166-168, 196]. Indeed, several components of the NFKB complex display
increased activity following PARylation [166, 168].
Inhibition of PARP 1 has repeatedly been demonstrated to decrease the severity of
inflammation in the intestines [197], pancreas [198], heart [199], brain [200], liver [201], and
many other tissues and model systems [202-206]. In particular, studies have shown that
inhibition of PARPI results in decreased inflammatory cytokine expression [166, 196, 207] [198,
202, 207, 208] decreased adhesion molecule production [207] [198] [203], decreased
inflammation-associated enzyme activity, including iNOS, COX2 and NADPH oxidase [203,
209], and decreased immune cell infiltration [198, 208, 210]. These molecular and cellular
alterations all support a model wherein PARPI activity contributes to increased inflammatory
signaling, and its inhibition protects the organism from inflammation-associated damage.
Accordingly, PARP inhibitors are experiencing significant clinical success as adjuvants in
multiple cancer therapies [211-213].
The BER glycosylase OGGI can also augment inflammation through NFKB. OGGI
bound to 8oxoG facilitates NFKB binding [214, 215] and increases expression of its pro-
inflammatory target genes [216]. Similar to inhibition of PARP 1, downregulation or knockout of
OGGI can also reduce inflammation severity [217-219]. Interestingly, the OGG1-8oxoG
complex acts as a guanine exchange factor and activates Ras family GTPases, further promoting
inflammation through the MEK/ERK pathway [220].
Proteins involved in double strand break repair have also been implicated in pro-
inflammatory signaling. DSBs can be recognized and bound by ATM, and RPA-coated single
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stranded DNA (an early intermediate of HR) is recognized by ATR. Multiple studies have shown
that ATM [152, 177, 178, 221] and ATR [221] can both promote NFKB signaling independent of
downstream DNA damage responses. Accordingly, ATM/ATR activity results in increased
cytokine production [177-179], and knockdown of ATM or ATR inhibits the production of the
immune cell-activating ligand NKG2D [221].
Finally, inflammation can be promoted by generalized DNA damage. For instance, the
growth arrest and DNA damage-inducible protein 34 (GADD34) is upregulated in response to
multiple types of cellular stress, including DNA damage and ER-stress [181]. In two models of
DNA damage-induced cancer, mice knocked out for GADD34 display significantly decreased
levels of pro-inflammatory cytokines, immune cell infiltration and malignant lesions [222] [223].
Cytosolic DNA, which can occur from viral infection, can also trigger activation of the pro-
inflammatory cytokines IL-i I [224] and IFNy [225] [226]. Thus, it is not necessary to initiate the
BER or HR pathways in the nucleus in order for DNA damage to induce inflammation.
The positive feedback relationship between DNA repair and inflammation is somewhat
unexpected, because repair of inflammation-derived lesions can promote inflammation further.
This mechanism may have evolved to ensure that inflammation persists long enough to
thoroughly remove the perceived insult before down-regulation to baseline levels. However, the
processes by which this positive feedback loop is suppressed have yet to be determined.
1.5 Inflammation Impairs Some DNA Repair Processes
In addition to direct damage by RONS, pro-inflammatory cytokines have also been shown to
contribute to DNA damage. This signal-induced damage is due in part to the cytokine-stimulated
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increase of intracellular RONS [32-34] and in part to impairment of some DNA repair
components [227-235]. Since RONS readily react with cysteine residues on proteins, many
cellular functions are susceptible to disruption from RONS [236]. Indeed, Jaiswal et al.
demonstrated that inflammatory cytokines were capable of both inducing DNA damage (as
measured by the comet assay) and impairing DNA repair activity (as measured by radiolabel
incorporation) via a NO-dependent mechanism [227].
More targeted studies have defined particular components of DNA repair that are
disrupted by inflammation. Reaction of NO with glutathione (GSH) produces S-
nitrosoglutathione (GSNO), which acts as a NO reservoir as well as a vehicle for cysteine
nitrosylation on other proteins. S-nitrosylation can have a variety of consequences for protein
function, such as altering activity or localization [237], and notable targets include DNA repair
enzymes. One of the most thoroughly studied targets of S-nitrosylation is the Direct Reversal
protein MGMT, which removes methyl lesions from nucleotides by directly transferring the
alkyl group onto a cysteine residue [107]. Nitrosylation of MGMT's active cysteine disables the
enzyme [238], causing an accumulation of the genotoxic lesion 0 6 -methylguanine [232]. While
DNA methylation is not a major type of inflammation-derived lesion, all DNA repair pathways
are essential for genomic maintenance, so inhibition of MGMT can increase stress on other
repair pathways to compensate. It is noteworthy that inflammation can increase sensitivity to
types of DNA damage that it does not produce directly.
Ironically, while BER is responsible for repairing many of the inflammation-induced
DNA lesions, it is also especially susceptible to disruption by inflammation. For instance, S-
nitrosylation of OGGl decreases its activity [233, 234, 239], and S-nitrosylation of APEl causes
it to be exported from the nucleus [229, 234]. Thus, two key steps in repairing oxidative damage
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can be impeded by excess NO. Additionally, some people have a common genetic variant of
OGGi (Ser326Cys), associated with increased lung cancer risk [240], which is susceptible to
inactivation by intracellular RONS following pro-inflammatory stimulation [228]. Finally,
rejoining broken DNA strands via ligase is the final step of most DNA repair pathways, and
evidence suggests that S-nitrosylation reduces ligase activity [235, 239], causing accumulation of
unresolved strand breaks that can be lethal or mutagenic.
Interestingly, and underscoring the complexity of the equilibrium between inflammation
and DNA repair, S-nitrosylation of AAG slightly increases its activity [234]. However, rather
than accelerating BER, increased AAG activity can produce more BER intermediates than the
downstream enzymes can efficiently process, leading to increased tissue damage and mutations
[131, 133]. Indeed, excess AAG has been shown to contribute to microsatellite instability in the
inflamed colon [146], highlighting the importance of balance among DNA repair components in
maintaining genomic integrity.
1.6 Inflammation <- 4 DNA Damage - Mutations + Cancer
The studies described here all contribute to the paradigm that inflammation and DNA damage
contribute to each other and to the development of cancer, but few have explicitly demonstrated
their direct connections. In seminal studies, the Samson lab has definitively shown that DNA
damage from inflammation drives cancer development [71, 241]. In one such illuminating study,
mice lacking the BER glycosylase Aag were treated with a colitis model of DSS in drinking
water. The Aag'~ animals developed far more severe tissue damage and neoplasia than wild type,
which correlated with a dramatic increase in DNA damage. Multiple types of base lesions
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accumulated, especially cA, and some genetic deletions were observed, suggesting aberrant
repair of broken replication forks. Sequencing tumors revealed point mutations in oncogenes that
correspond with the mutational signatures associated with inflammation [71]. Similar results
were obtained in stomach tissue when Aag-'~ and wild type animals were treated with H pylori, a
prevalent source of gastric inflammation and cancer [71, 242]. Another Samson lab study
demonstrated the importance of BER of deamination products during inflammation, observing
more severe pathology in DSS-treated Mbd4-'- mice compared to wild type [241]. The Samson
lab further established that DNA repair is essential to tolerating inflammation, as mice lacking
multiple repair enzymes could not tolerate even a single bout of DSS-induced colitis [72]. With
these targeted studies, the Samson lab has uniquely contributed to this field by directly
demonstrating the importance of DNA damage and its repair for tolerating inflammation.
Thus, we expand upon Figure 1-1 with the examples described in this paper to arrive at
Figure 1-11. Inflammation causes DNA damage primarily via RONS, which can produce DNA
base and backbone lesions both by direct reaction or production of reactive LPO intermediates.
The detection and response to DNA damage by BER (e.g., PARP, OGGI), HR (e.g.,
ATM/ATR), or generalized damage recognition can signal for increased inflammation, creating a
positive feedback loop. Inflammatory transcription factors such as NRF2 and NFKB can mitigate
the damage to DNA by neutralizing reactive chemicals with antioxidants and upregulating DNA
repair pathways. However, nitric oxide can impair some repair enzymes, complicating the
network and increasing the potential for dysregulation. Failure to repair DNA damage can lead to
the mutations that initiate cancer, and many physiological processes involved in inflammation
(e.g., proliferation, migration) also promote cancer development. Given the number of
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mechanisms by which DNA damage and inflammation stimulate each other, it is no wonder that
autoimmune and inflammatory diseases are so prevalent, difficult to control, and carcinogenic.
1.7 Transgenic In Vivo Mutation Assays
Measuring mutagenesis in vivo is essential to understanding the conditions that promote cancer.
Scientists have identified numerous animal models for quantifying different types of mutations.
Some in vivo mutation assays utilize endogenous gene loci, which are cost-effective because no
genetic manipulation is involved, but are generally limited to one or a few tissue types. Several
transgenic animal models have been created to detect mutations with reporter genes that are non
functional in the animal, enabling measurement of mutations across many tissues.
The first transgenic animals created for detecting mutations in vivo incorporated bacterial
genes flanked by lambda phage cos sites [243-245]. Since the transgenes do not produce
mammalian proteins, and since they were incorporated at genetic loci neutral to the development
and health of the animal, the transgenes are non functional in the life of the animal [246, 247]. In
these models, the assay is accomplished by treating the animal with the mutagen(s) of interest,
extracting genomic DNA, packaging the transgene with lambda phage, and infecting E. coli to
identify functional mutations in the extracted transgene. To improve assay sensitivity, the
bacterial genes are incorporated at high copy numbers [246].
The first two transgenic animal models designed under this strategy employed the lac
operon. In 1989, Gossen et al. described creation of the LacZ mouse (later renamed
MutaTMMouse), wherein the reporter contains the complete 3.9 kilobase (kb) bacterial LacZ
gene. Following treatment, the transgene is recovered from animal tissue and packaged into
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phage particles, used to infect Lac7 . coli, and plated on X-Gal plates. Mutants are then scored
as colorless plaques, indicating absence of 8-galactosidase, and normalized to non-mutant blue
plaques [243]. Similarly, the LacI mouse (later renamed BigBlue®) was created with the
complete 1080 bp LacI repressor gene, in which mutants produce blue plaques on X-Gal plates
and are normalized to non-mutant clear plaques [244]. Sequencing DNA from mutant samples
allows determination of the precise mutation that occurred.
In 1996, Nohmi et al. reported the creation of the Gpt-A mouse, which employs a similar
detection strategy as MutaTMMouse and BigBlue®, but features selection methods for detection
of two types of mutations. The gpt delta transgene contains the 456 bp gpt gene, which enables
detection of point mutations, as well as the red and gam genes to enable detection of deletions.
Point mutations in the gpt gene enable infected E. coli to grow on 6-thioguanine selection plates,
and deletion of both the red and gam genes causes sensitivity to P2 interference, enabling
detection as plaques in P2 lysogens of E. coli. While the MutaTMMouse and BigBlue® assays are
capable of detecting many types of mutations, sequencing is necessary to determine the type of
mutation that occurred. Thus, one significant advantage of the Gpt-A model is that two different
types of mutations can be assayed separately.
The MutaTMMouse, BigBlue® and Gpt-A animal models have been useful for studying
point mutations, frameshifts, small insertions, and deletions in many studies. Since the bacterial
target genes are generally short and present at high copy numbers, these animals can only detect
small-scale mutations [246]. However, many carcinogenic mutations result from large-scale
rearrangements during mitotic recombination [119, 124]. To complement the small-scale
transgenic in vivo mutation assays described above, the Engelward laboratory created the FYDR
42
Recombomouse, first reported in 2003 [248], as a method to detect large-scale genomic sequence
rearrangements.
FYDR transgenic mice contain a direct repeat of truncated copies of the EYFP gene,
where the 5' copy lacks the 5' coding region of the gene and the 3' copy likewise lacks the 3'
coding region (Fig 1-12). Expression of the truncated EYFP sequences does not produce a
fluorescent protein. However, if a DSB occurs within one of the copies, and the Rad51
nucleoprotein filament identifies the homologous sequence in the incorrect copy as the template
for repair, HDR will produce a sequence rearrangement that restores the full coding region of the
gene, and expression results in a full-length fluorescent EYFP protein [248]. Aberrant
recombination events can then be visualized as individual fluorescent foci within intact tissue, or
the total proportion of mutated cells can be measured by flow cytometry.
The FYDR transgene was randomly incorporated at a locus on Chromosome 1, and as a
result could only be detected in the pancreas and skin [249]. In order to create a more widely
usable animal model, the Engelward laboratory created targeting vectors to integrate a similar
direct repeat of truncated EGFP sequences at the ubiquitously-expressed Rosa26 locus [250].
This congenic animal model, called the Rosa26 Direct Repeat (RaDR) mouse, has enabled
fluorescent detection of sequence rearrangement mutations in every tissue studied so far [251,
252].
Other transgenic direct repeat animal models for detecting HR-driven mutations have
subsequently been created in other labs. The first of these was created in the Jasin laboratory,
utilizing a direct repeat of GFP sequences wherein the first is disrupted by an I-Scel restriction
site, and the second is truncated at both 5' and 3' ends [253]. Following induction of a DSB by I-
Scel, the cell can undergo gene conversion to produce a full length GFP. This model system has
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been useful for studying the genetic underpinnings and mechanisms of homologous
recombination [253, 254]. However, studies are limited to analysis of a single recombination
mechanism following an artificially induced DSB in primary cell cultures.
Recently, the Nakamura lab reported another direct repeat transgenic animal, this one
containing a partial duplication in the 3' region of the HPRT gene followed by a GFP sequence
[255]. The duplication causes inactivation of the HPRT gene, but loss of the duplication by
intrastrand recombination or sister chromatid exchange produces an HPRT-GFP fusion protein.
Similar to RaDR, this model permits in situ detection of spontaneous sequence rearrangements.
However, this model has not successfully detected gene conversion mutations, which is the
predominant mechanism of mitotic HR [256].
1.8 Approaches and Aims of This Thesis
The work described in this thesis was designed to interrogate the contributions of inflammation
and DNA damage to the development of mutations and cancer. We utilized RaDR fluorescence
as our primary readout of mutagenicity, because this animal model provides the simplest, least
laborious, and most cost-effective measurement of mutations in vivo. Despite the fact that
inflammation produces primarily single base lesions, which are more commonly associated with
point mutations, inflammation-induced DNA lesions can lead to strand breaks and replication
fork breakdown, initiating repair by HR as described above. Thus, our primary mutation readout
derived from large-scale sequence rearrangements can serve as a general indicator of
mutagenicity. Our RaDR mice also contain the Gpt-A transgene, enabling unprecedented
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analysis of sequence rearrangements, point mutations and deletions all within a single tissue
sample.
The causative relationship between inflammation and cancer has been thoroughly
established in the intestine [4, 7, 11], and so we designed our studies to query intestinal
inflammation's contributions to mutagenesis. Further lending itself to studies of mutations and
cancer, intestinal architecture is well defined and enables identification of somatic stem cells,
which can be difficult or impossible to identify in other tissues. The colon epithelium consists of
pore-like divots into the mucosa called crypts, and the small intestine also contains fingerlike
projections into the lumen, called villi. At the base of each crypt are one or more somatic stem
cells, which give rise to the proliferative transit cells that comprise the length of the crypt (Fig 1-
13A) and, in the small intestine, the villi surface [257]. The continual proliferation of stem and
transit cells enables continual renewal of crypt (and villus) epithelia. Transit cells are eventually
sloughed off into the lumen, and stem cells produce complete epithelial turnover within 3-5 days
[258]. In a RaDR animal, mutations in crypt stem cells are visible as large, bright, roughly
circular foci that can be distinguished from the smaller, dimmer and/or irregularly shaped foci of
mutated transit cells (Fig 1-13B). Colon epithelia can be disaggregated into a suspension of
crypts, and both partially and fully fluorescent crypts are visible in suspensions of RaDR crypts
(Fig 1-13C). The foci that we believe to be converted crypts are, on average, lOx brighter and 6x
larger than foci that appear to be single cells (Fig 1-13D). Since somatic stem cells persist for
years, if not the animal's lifetime, whereas transit cells are sloughed off within 5 days, it is of
great interest to quantify recombinant stem cell foci rather than all foci.
To distinguish crypt foci from transit cell foci with minimal bias, we collaborated with
Dr. Dushan Wadduwage to write MATLAB image analysis programs. This program uses
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gradient and intensity features of the image to distinguish RaDR foci from background
autofluorescence. The first version of this program identifies all foci within the tissue and is
useful for many tissues, such as pancreas and liver, where foci may assume different sizes and
shapes due to tissue architecture and morphology. Another version of the program specifically
identifies crypt foci based on size, shape and intensity through a training algorithm. The user
annotates 3-4 images from the data set for purported crypt foci, which the program interprets to
define crypt foci parameters, and then applies those parameters to analyze all images in the data
set. Thus, we are able to analyze tissue for all foci as well as crypt foci.
RaDR mutants can also be quantified according to the proportion of the tissue that is
fluorescent. The simplest method for quantifying proportion of fluorescent cells is by flow
cytometry, but this requires disaggregation of the tissue, so de novo mutations cannot be
distinguished from clonally expanded mutants and the context of the mutation in situ is lost. We
can also approximate the overall mutant proportion in RaDR tissue images by comparing the
fluorescent area to the total tissue area. Measuring the percent area of fluorescence in the tissue
is of particular utility in measuring RaDR mutations in intestinal tumors, where crypt
architecture is obliterated and clonal expansion produces patches of fluorescence.
We utilized these methods to quantify mutagenesis from several model systems. The
second chapter of this thesis discusses mutagenic consequences of eliminating regulatory
elements of the immune system. Next, we explored mutagenesis and clonal expansion resulting
from microbially induced inflammation. Finally, we evaluated mutations arising from
upregulated base excision repair. Overall, our results indicate that inflammation does not cause a
significant increase in de novo sequence rearrangement mutations, but it contributes to cancer in
part by increasing the total burden of mutant cells via clonal expansion.
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Chapter 2
Roles of Immune Regulation in Initiation of Sequence Rearrangement
Mutations
2.1 Abstract
Chronic inflammation is a major risk factor for cancer, but its roles in cancer initiation and
promotion have yet to be fully delineated. Cancer arises from the accumulation of genetic
alterations (i.e., mutations and epigenetics), and inflammation is known to promote mutations,
but it remains unclear whether the mutations caused by inflammation drive cancer or simply
accelerate it. Furthermore, it is unclear whether inflammation must be severe, chronic, and/or
dysregulated to be carcinogenic. In this study, we utilized the RaDR transgenic mouse, which
allows in situ detection of sequence rearrangement mutations, to query how different aspects of
inflammation regulation impact mutagenesis. First, we examined the accumulation of RaDR
mutations in unchallenged immunocompromised mice to determine whether regulation of the
innate immune system has a role in preventing or promoting mutagenesis. Second, we evaluated
RaDR mutations in ApcMin/ mice, which contain a driver mutation for intestinal cancer, and were
given an anti-inflammatory treatment. The first of these studies revealed that impairment of the
adaptive immune system may promote mutagenesis, suggesting a role for dysregulated
inflammation in cancer initiation. Attenuation of endogenous inflammation reduced tumor
multiplicity as well as overall burden of recombinant cells in the tissue, but we did not observe a
significant reduction in recombination frequency indicating that inflammation promotes cancer
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through mechanisms aside from de novo mutagenesis. Together, these studies indicate that while
adaptive immunity may protect against mutations, the promotion of cancer by inflammation does
not rely on increased mutagenesis.
2.2 Introduction
Chronic inflammatory diseases, such as Crohn's disease, ulcerative colitis, pancreatitis, and
hepatitis, are major risk factors for cancer. Inflammation contributes to cancer development in a
variety of ways, and one of the most important is that inflammation causes DNA damage, which
leads to mutations. During inflammation, innate immune cells produce large amounts of reactive
oxygen and nitrogen species (RONS) evolved to destroy pathogens, but those chemicals can also
damage the body's own DNA. Dysregulation of the innate immune system can lead to
autoinflammatory diseases, a form of autoimmunity, wherein RONS are produced excessively
and often not in response to an insult, causing a great deal of host tissue damage [1].
Chronic inflammatory diseases are difficult to characterize because they generally act in
bouts or cycles of severe inflammation with periods of relatively normal physiology in between
[2-4]. The timing and kinetics of these bouts can be unpredictable, making controlled studies of
dysregulated inflammation difficult to define [5, 6]. Since inflammatory diseases strongly
predispose patients to cancer, it is of great interest to determine what aspects of inflammation
contribute to mutagenesis during cancer initiation and promotion.
It is broadly hypothesized that cancer undergoes a multistage developmental process:
initiation, promotion, and progression. Initiation refers to the stage where a cell or cells develop
one or more oncogenic driver mutations, and promotion describes the clonal expansion of
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initiated cells and accumulation of further mutations within the lineage. Importantly, genomic
instability and progressive mutagenesis are hallmarks of cancer, enabling tumor cells to evolve
increased malignancy and drug resistance over time (Fig 2-1). Thus, mutations accumulate
through all stages of cancer development, contributing not just to initiation, but all stages of
cancer progression. Inflammation displays features of both initiation, in that it can induce
mutations, as well as promotion, because the inflammatory microenvironment facilitates growth
and cellular migration. Indeed, it is likely that inflammation can impact both stages of
carcinogenesis. In this work, we utilized animals that contain a fluorescent reporter transgene to
detect sequence rearrangement mutations [7] to query how different aspects of inflammation
impact mutagenesis.
To study mutagenesis, we utilized the RaDR mouse model, which allows detection of
sequence rearrangement mutations in situ. The RaDR mouse was created with a tandem repeat of
truncated EGFP coding sequences inserted at the Rosa26 locus for ubiquitous expression [8].
The 5' copy of the EGFP gene contains a deletion in the 5' region of the sequence, and likewise
the 3' copy has a deletion of the 3' end of the gene. Cells that contain the un-mutated transgene
express the truncated sequences, which do not produce a fluorescent product. However, if there
is a double strand break (DSB) in one of the EGFP genes during S or G2 phase, homologous
recombination (HR) may errantly produce a sequence rearrangement mutation as it repairs the
breakage. For example, if the DSB occurs in the 3' copy, then during homology searching of HR,
the cell may identify the homologous region of the 5' copy on the sister chromatid, producing a
full-length EGFP gene. The resulting mutated cell and all of its progeny then express EGFP and
can be identified by fluorescent microscopy or flow cytometry. For more detailed descriptions
and validation of the RaDR mouse, please see [7]. Importantly, although HR is widely
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considered an "error-free" DNA repair mechanism, the presence of many repetitive elements
throughout the genome [9] presents many opportunities for HR to cause insertions, deletions and
loss of heterozygosity [10-14]. Numerous studies have identified HR as a mechanism by which
cancer cells may acquire these mutations [15-20]. Therefore, the RaDR animal provides a
relevant proxy for quantifying mutagenesis within a tissue.
To study whether inflammation contributes to possible initiating mutations, we aged
animals that lack key regulatory elements of inflammation with no additional manipulation.
Therefore, any differences in mutation accumulation would be derived from the animal's
deficiencies in regulating its innate immune system. This model system allowed us to assess
aspects of innate immune regulation for mutagenicity without inducing inflammation, which
could potentially obscure results.
We also studied the potential for inflammation to promote cancer and mutations using
animals that contain a cancer driver mutation (ApcMin+) and thus spontaneously develop
intestinal tumors. By inhibiting the prominent pro-inflammatory cytokine TNF in these animals,
we reduced inflammation's contribution to cancer promotion, allowing us to determine whether
inflammation promotes mutagenesis as well as tumorigenesis in this model.
2.2.1 Rag2~'~ and Rag2-';IL10~- animals lack key factors involved in regulation of
inflammation
The immune system comprises a network of cells and signals that co-regulate to optimize
responses to pathogens. Whereas the innate immune system's macrophages and neutrophils
produce non-targeted reactive chemicals that damage any biomolecule they contact (in addition
to phagocytic and antigen-presenting functions), the adaptive immune system identifies and
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attacks specific pathogens with minimal collateral damage. The adaptive immune system helps
regulate and redirect the innate immune system to prevent self-injury when possible [21-23]. For
example, effector T cells have been shown to block macrophage activity, neutrophil recruitment
and pro-inflammatory cytokine secretion [24, 25], and regulatory T cells (Tregs) suppress the
innate immune system to reduce inflammation [22, 23, 26]. However, it is unclear if the adaptive
immune system has any impact on the development of mutations, either on its own or through
moderation of the innate immune system.
In order to query whether the adaptive immune system plays a role in preventing or
promoting mutagenesis, we crossed the RaDR transgene into Rag2-'~ mice, which lack a
functional adaptive immune system [27]. In order for B and T cells to mature and function, they
must undergo a series of genetic rearrangements to produce unique antibodies and T cell
receptors. The Rag2 gene is essential for an early step of this process, called V(D)J
recombination. When Rag2 is absent, B and T cells never reach maturity and the adaptive
immune system is unable to function. Therefore, with a non-functional adaptive immune system,
a layer of innate immune regulation is lost.
Another important regulatory element of the immune system is the anti-inflammatory
cytokine IL10. This pleiotropic cytokine downregulates macrophage stimulation [28-30] and
blocks NFKB [31, 32], and it is thus heavily involved in regulating inflammation. Indeed,
production of IL- 10 is one mode by which Tregs suppress innate immune inflammation [22].
Since IL10 plays key roles in moderating the innate immune system, we also bred RaDR mice
with Rag2~J-;IL10-'- animals in order to see whether the absence of this cytokine promotes
mutagenesis.
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2.2.2 Apc""'+ animals spontaneously develop inflammation and cancer
In an effort to focus on inflammation's contributions to the promotion stage of cancer, we
attenuated inflammation in animals that contain an oncogenic driver mutation by treating with an
antibody against the pro-inflammatory cytokine TNF.
Apcmin/+ (Min) animals have been used to study intestinal carcinogenesis for decades.
They contain an inactivating point mutation in the tumor suppressor Apc, which results in
spontaneous intestinal tumorigenesis within the first two months of life. The Min model can be
considered as all cells already having an initiating mutation, which is why tumors develop so
quickly, and also why this model lends itself to studying cancer promotion (Fig 2-1). The Min
phenotype also includes elevated metrics of systemic inflammation, splenomegaly, thymic
involution, and lymphodepletion [33, 34].
TNF is a multifunctional cytokine that is secreted primarily by macrophages to promote
inflammation [35]. The far-reaching effects of TNF are perhaps best illustrated with the range of
diseases that can be effectively treated by blocking the cytokine, including rheumatoid arthritis,
inflammatory bowel disease and psoriasis [35]. Previous studies have shown that mitigating Min
animals' endogenous inflammation with anti-TNF significantly reduced tumor burden, and
possibly even induced regression [36]. We aimed to recapitulate this treatment paradigm with
RaDR Min mice to determine whether suppression of inflammation by anti-TNF affects
mutagenesis as well as tumorigenesis.
78
2.3 Materials and Methods
2.3.1 RaDR vs. Rag2~1~;RaDR vs. Rag2/~;IL10';RaDR
RaDRRR, Rag2--;RaDR R, and Rag2~1;IL10-;RaDR RRmice were housed in an AAALAC-
accredited barrier facility free of known murine Helicobacter species, viruses, Salmonella
species, Citrobacter rodentium, ecto- and endoparasites. Rag2-l-;IL10-/- mice were maintained in
SCID housing, while WT and Rag2-1- mice were housed in normal clean cages. Animals were
aged with no manipulation for 6 months, at which time they were euthanized by CO2 according
to AVMA guidelines and necropsied with standard procedures. Samples collected and analyzed
immediately included: body weight, spleen weight, thymus weight, pancreas RaDR imaging,
liver RaDR imaging, colon RaDR imaging, mammary RaDR imaging.
2.3.2 Anti-TNF treatment in RaDR;Apc Mi"+ mice
C57B1/6 RaDR/R and C57B1/6 ApcM'"I+ animals were bred to produce RaDRR/+;APcMi"n" and
RaDRRI offspring. The animals were separated by sex and housed in large cages containing up
to 10 mice per cage. Each cage contained both Min and wild type mice, and mice of each
genotype were split evenly into anti-TNF and sham treatment groups. Mice began receiving i.p.
injections of anti-TNF antibody (XT3. 11, BioXCell, West Lebanon NH) or anti-IgG sham
antibody (HRPN, BioXCell, West Lebanon NH) at 3.5-4 months of age. The initial loading dose
was 0.4 mL of 1 mg/mL antibody diluted in sterile PBS, and subsequent injections were 0.2 mL
of 1 mg/mL antibody given three times a week for a total of 6 weeks. At the end of the 6-week
treatment period, mice were euthanized by CO 2 according to AVMA guidelines and necropsied
with standard procedures. Samples collected and analyzed immediately included: body weight,
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complete blood count, spleen weight and RaDR flow, thymus weight and RaDR flow, pancreas
RaDR imaging, liver RaDR imaging, mammary RaDR imaging, and intestine segment RaDR
imaging. Samples collected and stored included: serum (-80'C), feces (RNA-later, -80'C),
spleen portions (RNA-later, -80'C and formalin, room temperature) thymus portions (RNA-later,
-80'C and formalin, room temperature), pancreas portion (formalin, room temperature), intestine
segment portions (RNA-later, -80'C), whole intestine segments (on bibulous paper in formalin,
room temperature), and lymph tissue from the mammary, mesentery, Peyer's patch and ceco-
colonic lymph nodes (RNA-later, -80'C). Animal carcasses were saved in formalin.
2.3.3 RaDR Necropsy and Tissue Imaging
Animals were euthanized with CO 2 according to AVMA guidelines. Tissues were excised and
held on ice in tubes containing PBS (mammary, spleen) or PBS with 0.0 1% trypsin inhibitor
(T9008 Sigma-Aldrich or P-1540 Westnet Inc) (pancreas, liver, intestines) until use. Intestines
were cut open on one side and the lumen was rinsed of fecal matter before placing in PBS +
trypsin inhibitor. Mammary, pancreas, liver and intestine tissues were compressed to 0.5 mm
between coverslips and imaged for EGFP under the Ix objective with the FITC filter of a Nikon
80i fluorescent microscope.
2.3.4 RaDR Image Analysis
RaDR images can be analyzed for the number of de novo recombination events by quantifying
individual fluorescent foci, or for total burden of recombinant cells by measuring the fluorescent
area of the tissue. Both metrics are normalized to tissue area, measured in ImageJ. To quantify
fluorescent foci, Dushan Wadduwage of Peter So's laboratory designed MATLAB-based
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programs that use gradient and intensity features of the image to distinguish individual foci
(manuscript under review). The program "FociCounter_3.1" was used to enumerate all foci in
pancreas, liver, and mammary tissues, and the program "17.03.27_Crypt counter with GUI" was
utilized to enumerate converted colonic crypts. The crypt counting program is trained to
recognize crypt foci based on 3-4 researcher-annotated images from the data set, then the
program is able to apply those parameters to identify crypt foci in other images. To quantify the
fluorescent area within the tissue, conservative intensity thresholds were set in ImageJ such that
background and artifactual fluorescence was excluded, and only brightly fluorescent pixels
would be measured. After marking the outline of the tissue, the area of pixels above the threshold
intensity were measured as well as the total tissue area.
2.3.5 RaDR Flow Cytometry
Tissues analyzed by flow cytometry were processed after imaging was completed. Briefly,
tissues were placed in 5 mL of 2 mg/ml collagenase type V (C9263, Sigma) in HBSS (Life
Technologies) in a GentleMACS C tube and mechanically dissociated with the GentleMACS
tissue grinder (Miltenyi Biotec). After mechanical disaggregation, the tissues were placed in a
37C incubator for 40 minutes to allow collagenase to degrade connective tissue. Cell suspensions
were then triterated 10-15 times and passed through a 70 micron cell strainer into 10 mL of cold
media (DMEM + 10% FBS + pen/strep) to halt collagenase digestion. The samples were then
centrifuged at 180 x g for 10 minutes and supernatant was discarded. The cell pellet was
resuspended in 350-500 uL of Opti-MEM reduced serum media (ThermoFisher Scientific) and
held on ice until analyzed. The samples were analyzed by a FACScan or FACS Calibur flow
cytometer for green fluorescence (530 nm) and red (585 nm) to account for autofluorescence.
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2.3.6 Tumor Quantitation
Following RaDR imaging, intestine segments were laid flat on bibulous paper and fixed in 10%
formalin. After several days, the formalin was discarded and replaced with 100% ethanol for 24
hours. The ethanol was then discarded and replaced with 70% ethanol. To count tumors, intestine
segments were carefully removed from the bibulous paper cassettes and placed on a stereoscopic
lOx microscope. The approximate sizes and locations of tumors within each segment were
recorded on paper.
2.3.7 Histopathology
Formalin-fixed tissues were embedded in paraffin, cut in 5 pm sections, and stained with
hematoxylin and eosin. Sections were scored by a pathologist blinded to sample identity. For
intestines, after tumors had been counted, intestine segments were rolled into swiss rolls and
placed in cassettes for paraffin embedding.
2.3.8 Immunofluorescence
Formalin-fixed tissue sections were embedded in paraffin and cut in 5 tm sections. Slides
stained for immunofluorescence were first deparaffinized with three five-minute washes in
xylenes, two five-minute washes in 100% ethanol, and 10-minute washes each in 95% ethanol,
90% ethanol, and 70% ethanol. Slides were washed twice in PBS, then boiled in Dako citric acid
antigen retrieval buffer (S1700, Agilent Technologies, Santa Clara, CA) for 30 min. After
cooling, slides were washed twice in diH20 and tissue sections were circled with hydrophobic
marker. Sections were blocked for one hour with 5% BSA + 0.3% Triton in PBST at room temp.
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All antibodies were diluted in 1% BSA + 0.3% Triton in PBST, and sections were stained
overnight at 4C. Slides were then washed three times for five minutes each in PBST and
incubated with the appropriate secondary antibody for one hour at room temperature. Slides were
then washed five times in PBST for five minutes each. Finally, a drop of DAPI with ProLong
AntiFade reagent was placed on the section, and a cover slip was laid overtop and sealed with
clear nail polish.
Primary antibodies used were: anti-Ki67 (Abcam ab15580, rabbit), anti-phospho-H2A.X
Ser-139 (Millipore 05-636, mouse), anti-nitrotyrosine (Millipore AB541 1, rabbit), and anti-
F4/80 (Abcam ab6640, rat). Secondary antibodies used were: Alexa Fluor 647 (goat anti-rabbit)
(used for both Ki67 and nitrotyrosine, but not simultaneously), Alexa Fluor 488 (goat anti-
mouse), Alexa Fluor 568 (goat anti-rat).
2.3.9 Statistical Analyses
RaDR foci were quantified as the number of foci per square centimeter of area (foci/cm 2), and
RaDR flow cytometry measurements were given as % fluorescent* 106 . Due to the fact that the
distribution of EGFP-positive cells in RaDR mice is non-normal across tissues and among
individuals, RaDR data sets were compared by Mann-Whitney U-test. It was not clear that tumor
multiplicity was normally distributed between individuals, and therefore tumor counts were also
compared by Mann-Whitney U-test. Body and tissue weights were compared by unpaired
Student's t-test. All statistical comparisons were calculated using GraphPad Prism 5.
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2.4 Results
2.4.1 Rag2'1 and Rag2~1~;IL1J~ develop more sequence rearrangement mutations than wild
type in the pancreas
The primary endpoint of interest in these studies is mutagenicity, which we evaluated with the
RaDR transgenic mouse for detecting sequence rearrangement mutations. When cells acquire the
RaDR mutation, fluorescent foci are visible in situ by fluorescence microscopy. As mutated cells
divide, the fluorescent progeny remain in close spatial proximity, creating larger foci. Therefore,
de novo mutations are quantified by enumeration of distinct foci. In intestine tissue, where well-
defined tissue architecture includes somatic stem cells that give rise to crypts, somatic stem cell
mutations can be identified and quantified by characteristic large, round foci.
During necropsy, the pancreas, colon, and left lobe of the liver were excised and imaged
for RaDR mutations. The number of foci and area of the tissue were initially quantified
manually, and later analyzed with MATLAB foci counting software (manuscript under review).
Colon images were analyzed for all foci as well as converted crypts. Surprisingly, there was a
significant increase in the number of mutations that occurred in Rag2-'- animals' pancreata (Fig
2-2A), indicating that either the adaptive immune system or Rag2 itself impacts the development
of pancreatic mutations. There were no significant differences between strains in the density of
mutant foci in the liver and colon tissue (Fig 2-2B and C).
In order to study why Rag2-'- pancreata develop more mutations, we examined histology
sections from 5-6 animals for each strain of mice. A trained pathologist blinded to sample
identity scored pancreas sections for pathology and noted observations (Table 2-1). Consistent
with the fact that these mice were not exposed to any inflammatory stimuli, the pancreata of each
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strain did not show signs of inflammation nor other pathology (Fig 2-3). We also stained
pancreas sections for molecular markers that could indicate causes for increased mutagenesis.
First, we stained for nitrotyrosine (3-NT) as a marker for nitrosative protein damage, a feature of
inflammation (Fig 2-4A). We also stained for the presence of F4/80-positive macrophages to
determine if the innate immune system was upregulated in mice that lacked adaptive immunity.
For both markers of inflammatory stress, there were no differences between genotypes (Fig 2-
4B).
Since RaDR mutations arise from HR, and HR generally occurs at double strand breaks
(DSBs) during S or G2, we also stained sections of pancreas tissue for proliferation with Ki67
antibody and DNA DSBs with yH2AX antibody. While HR-derived mutations should correlate
with proliferation and DSBs, we did not observe differences in Ki67 nor yH2AX staining among
mouse strains (Fig 2-4C).
These results show that, at the time of necropsy, there were no significant differences in
inflammation, proliferation, nor DSBs that could explain the increase in RaDR foci in Rag2'-
pancreata.
2.4.2 Rag2- and Rag2-1-;IL1O-/ have smaller lymphoid organs than wild type
As a surrogate measure of overall health, body weights were measured at the time of necropsy.
As hypothesized, since all animals are 129 background and unchallenged, the animals developed
normally and had similar body weights at necropsy (Fig 2-5A). Weights of the thymus and
spleen were also measured for each mouse at necropsy. Consistent with previous reports, the
spleen and thymus of Rag2-/- animals are smaller than that of WT mice [37, 38] (Fig 2-5B).
Since the spleen and thymus are the organs in which B and T lymphocytes complete maturation,
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and the Rag2 gene is essential for B and T cell maturation, it is unsurprising that both knockout
strains have smaller lymphoid organs than wild type animals.
2.4.3 Anti-TNF treatment decreases intestinal inflammation, tumor multiplicity, and
mutant burden in ApcMin/+ mice, but does not affect mutation frequency.
To complement our studies of mice lacking regulatory components of the immune system, we
utilized the ApcM"nl mouse model of intestinal cancer. Apc is a tumor suppressor gene that
regulates the Wnt signaling pathway, and over 80% of human colon cancers contain Apc
mutations [39, 40]. Min mice are heterozygous for an inactivating point mutation in Apc and
were named for their spontaneous development of multiple intestinal neoplasia [41, 42]. These
animals accumulate intestinal adenomatous polyps starting within two months of life, with the
majority arising in the distal third of the small intestine (ileum). Whether inflammation promotes
cancer in these mice or is merely a symptom of cancer development has not been determined, but
studies have shown that mitigation of inflammation reduces Min tumor development [43-46]. In
this experiment, we aimed to recapitulate findings of Rao et al. showing that anti-TNF treatment
decreases tumorigenesis [36], and to contribute information regarding whether reducing
inflammation affects mutagenicity as well.
Min and WT littermates were divided evenly between anti-TNF and sham antibody
treatments as described above. Animals were separated by sex, but both genotypes and treatment
groups were cohoused in large cages to limit the potential for confounding variables such as
microbiota. Our treatment regimen closely paralleled that of the Rao et al. study, and indeed we
also observed fewer polyps in the Min ileum (Fig 2-6) and an overall reduction in intestinal
inflammation (Fig 2-7).
86
Although intestinal tumorigenesis decreased with anti-TNF treatment, the frequency of
mutant crypts did not vary significantly between genotypes nor treatments (Fig 2-8A). However,
quantifying the overall burden of mutant cells revealed that although mutation frequency did not
increase, Min ilea and colons had a greater burden of mutant cells compared to WT, and anti-
TNF treatment decreased the overall mutant burden in Min ilea (Fig 2-8B). The fact that ileal
polyps and overall mutant burden both decreased with anti-TNF treatment while de novo
recombination mutations were unchanged indicates that reducing inflammation also reduces
tumorigenesis, but it does not significantly impact the production of sequence rearrangement
mutations. Thus, the decreased overall mutant burden in anti-TNF treated animals probably
results from decreased proliferation corresponding to decreased tumorigenesis.
Although our target tissues for this experiment were intestines, we also analyzed
pancreas, liver, mammary, and spleen tissues for RaDR mutations. Pancreas, liver and mammary
mutation frequencies were quantified as foci in fluorescent images, and there was no difference
in the number of de novo sequence rearrangements in any of these tissues (Fig 2-9A). The total
proportion of fluorescent cells in the tissue was also measured by flow cytometry. By this metric,
Min mice were found to have significantly higher proportions of mutant cells than WT in anti-
TNF treated pancreata and sham-treated livers (Fig 2-9B). This increase in total recombinant
cells in the Min pancreas and liver can likely be attributed to dysregulated Wnt signaling causing
increased proliferation.
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2.4.4 ApcM""/+ mice suffer from low body weight, thymic involution, and splenomegaly, and
anti-TNF treatment minimally improves those metrics
Min mice exhibit a number of pathologies that worsen with age, including: elevated intestinal
inflammation, cachexia, splenomegaly, lymphodepletion, and premature thymic involution [33,
34, 47, 48]. We compared these pathologies between genotypes and treatment groups as
measurements of overall health.
Min mice were smaller than WT and had much larger spleens (Fig 2-1 OA, B), as
expected for this strain [34]. Also consistent with Min physiology, thymi of sham-treated Min
mice were smaller than WT (Fig 2- 1C) [33, 34]. Anti-TNF treatment appeared to result in
larger thymi for both Min and WT animals, but this effect was only statistically significant in
Min mice (Fig2. 1 OC). Given the trends of increased lymphoid organ size, it is possible that anti-
TNF treatment attenuates lymphodepletion in Min mice, but this has not been quantified.
Interestingly, Min animals had a significantly lower proportion of mutated spleen cells
compared to WT (Fig 2-9B). Min mice are known to suffer depletion of lymphocytes, which
compose the splenic white pulp, and a greatly increased mass and proportion of red pulp, which
contains hematopoietic cells [34]. Identification of which spleen cell types acquire the RaDR
mutation could reveal the physiological explanation for the decreased proportion of mutated cells
in the Min spleen.
2.5 Discussion
In the studies described here, we aimed to ascertain whether modulating regulatory elements of
innate immunity could contribute to or protect against mutations. We compared wild type
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animals to those that lack a functional adaptive immune system (Rag2~'~) as well as animals
lacking both adaptive immunity and an important anti-inflammatory cytokine (Rag2'~;IL1-),
because both the adaptive immune system and ILI0 play major roles in regulating the innate
immune system and inflammation. We aged animals for six months with no manipulation so that
all animals were healthy and exposed only to their commensal microbiota; thus, mutations were
not induced but would arise from normal physiology. We hypothesized that animals lacking key
regulatory elements of inflammation may experience increased levels of RONS throughout their
lives, contributing to an increase in mutagenesis.
Previous studies using a plasmid assay analogous to the RaDR transgene have shown that
inflammatory RONS are indeed capable of inducing mutations through homologous
recombination [49, 50]. During inflammation, replication blocking lesions and single strand
breaks can arise from direct reaction with RONS or as intermediates during Base Excision
Repair, and these lesions can be recombinogenic, particularly during cell division [49-51].
Subsequent in vivo studies demonstrated that inflammation during cellular proliferation
synergistically increases mutagenesis in the pancreas [52], but the contributions of inflammation
to mutagenesis had not yet been quantified in other tissues.
Interestingly, we did observe an increase in mutations in both Rag2~'~ and Rag2--;JL10~-
pancreata as compared to wild type, though there was no significant difference between Rag2-'-
and Rag2-1~;IL10-'- pancreas mutations. This supports our hypothesis that knockout of functional
adaptive immune cells leads to increased mutagenesis, possibly through innate immune
dysregulation. We therefore sought to explore how the adaptive immune system protects the
pancreas from sequence rearrangements. To determine whether inflammation was present, we
evaluated pancreas sections for histopathology scores, nitrosative tissue damage, and
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macrophage infiltration, but observed no quantifiable differences between strains. Since HR-
derived sequence rearrangement mutations generally arise from mis-repaired DSBs during
cellular proliferation, we also assayed pancreas sections for yH2AX (DSBs) and Ki67
(proliferation). Again, we did not observe quantifiable differences between strains.
It is important to note that immunofluorescent staining only captures the physiology of
the tissue at a single point in time, whereas RaDR-mutated cells have accumulated throughout
the 6 months of the animal's life. Thus, while staining does not indicate measurable differences
in inflammation, proliferation, nor DSBs at the 6 month timepoint, there may have been
differences in any of these metrics earlier in the animal's life that contributed to the increased
formation of sequence rearrangement mutations. It is also possible that a very low degree of
inflammation is present in Rag2~'~ animals, but to such a small extent that it cannot be
distinguished in tissue sections.
Our hypothesis as to why Rag2~1 mice develop more HR-driven mutations is that RAG2
may play a role in DSB repair pathway choice. Gigi et al. demonstrated that the C-terminus of
the RAG2 protein promotes canonical non-homologous end joining (c-NHEJ), and that
truncation of the RAG2 protein at the C-terminus promotes alternative NHEJ (alt-NHEJ) in
V(D)J recombination during lymphocyte development [53]. Other studies have shown that Rag2
restricts DSB repair to c-NHEJ in embryonic stem cells [54]. We hypothesize that deletion of the
Rag2 gene diminishes the choice for c-NHEJ during DSB repair, and HR compensates. We also
hypothesize that this effect is only observable in the pancreas because the pancreas accumulates
up to an order of magnitude more mutations than the other tissue types studied, and thus the
differences in other tissues is not as pronounced. However, Rag2 is thought to be a lymphoid
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cell-specific gene [55], and data repositories report no detectable expression of Rag2 in the
pancreas [56]. Thus, more studies are necessary to test these hypotheses.
We also studied the effects of inflammation on the promotion phase of carcinogenesis.
We treated Min mice, which contain a cancer driver mutation and spontaneously develop
intestinal tumors and inflammation, with anti-TNF to mitigate systemic inflammation. Previous
studies have shown that inflammation strongly promotes cancer development [36, 43, 57, 58],
but whether that includes increased mutagenesis has not been elucidated. Our studies reproduced
previous findings that anti-TNF reduced tumorigenesis in Min mice [36] [other refs], and
contributed the endpoint of accumulated sequence rearrangement mutations. Our results indicate
that reducing inflammation in mice that already contain a cancer driver mutation helps to
decrease tumor multiplicity but has little effect on sequence rearrangement mutagenesis, at least
at the RaDR locus. This suggests that while inflammation helps promote tumor development,
this promotion does not depend on increased mutagenesis.
Together, these studies suggest that while regulation of inflammation may protect against
mutagenesis, the mechanism by which inflammation promotes cancer is not dependent on
increased mutagenesis.
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Progressive acquisition of genetic modifications (mutations,
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Figure 2-1. Stepwise model of cancer progression and context of experimental setups
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Figure 2-2. RaDR mutation frequency. At necropsy, pancreas, liver and colon tissues
were excised and imaged for fluorescent foci. Foci were quantified by MATLAB
automated image analysis and normalized to tissue area. (A) Pancreata of Rag2'
animals developed significantly more de novo recombination events compared to
WT. Rag2-';L10' pancreas foci were not statistically different from Rag2'. (B, C)
RaDR foci in the liver (B) and colonic crypts (C) were not statistically significant
between genotypes. Bar indicates median. Mann-Whitney U-test, 4p < 0.0001.
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Figure 2-3. Pancreas histology sections. A pathologist blinded to sample
identity scored pancreata for signs of inflammation and other pathology. No
differences were found between genotypes.
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Table 2-1 Pathologist Observations of Pancreas Histology Sections
Sample ID PANCREAS pathology Notes (random, rather Insignificant findings) Genotype pancreas (ctanm
14-2801 Without pathological findings Rg2__;IL1O'1- 253
14-2802 Without pathological findings Small-sized single area of cytological alteration (eosinophilic focus) Rog2- 324
14-2 803 Without pathological findings Small-sized areas (3) of cytological alteration (eosinophilic foci) WT 93
14-2804 Without pathological findings Small-sized areas (3) of cytological alteration (eosinophilic foci) Rog2 1 ;1L10+ 417
Small-sized single area of cytological alteration (eosinophilic focus)
14-2 805 Without pathological findings Ocassional pancreatic acinar cell vacuolation, minimal WT 194
Peripancreatic fat, focal granulomatous inflammation
14-2806 Without pathological findings Focal pancreatic acinar cell vacuolation, minimal Rog2- 357interlobular edema which is probably an artifact (very small piece)
14-2807 Without pathological findings Small-sized areas (2) of cytological alteration (eosinophilic foci) Rag2- 409
14-2808 Without pathological findings Small-sized areas (3) of cytological alteration (eosinophilic foci) Rag2*l 402Focal acinar cell degeneration (small, unremarkable)
14-2809 Without pathological findings Focal pancreatic acinar cell vacuolation, minimal WT 233Focal acinar cell degeneration (small, unremarkable)
14-2810 Without pathological findings Several small-sized areas of cytological alteration (eosinophilic foci) WT 115
14-2122 Without pathological findings Focal pancreatic acinar cell vacuolation, minimal Rog21;Liig1 381Peripancreatic fat, single small focal granulomatous inflammation
14-2121 Without pathological findings Small-sized single area of cytological alteration (eosinophilic focus) Rag2 1 ;LIO1 349
14-2120 Without pathological findings Small-sized areas (3) of cytological alteration (eosinophilic foci) WT 239Peripancreatic fat, single small focal granulomatous inflammation
14-2119 Without pathological findings Several small-sized areas of cytological alteration (eosinophilic foci) WT 182
14-2118 Without pathological findings Rag2+;ILUI' 363
14-2812 Without pathological findings Rag2 1 ;1L101  250
14-2 811 Without pathological findings Small-sized single area of cytological alteration (eosinophilic focus) Rog2-1- 311Focal pancreatic acinar cell vacuolation, minimal
Ki67
3-NT F4/80 H2AX
WT
Rag2-1-
Figure 2-4. Immunofluorescence staining for markers of inflammation do not indicate differences between WT
and Rag2- pancreata. Sections of pancreas tissue from three WT and five Rag24 animals were used to stain
for nitrosative tissue damage (3-nitrotyrosine, A), macrophage presence (F4/80, B), DNA double strand breaks
(yH2AX), and proliferation (Ki67) (C). F4/80 and 3-Nitrotyrosine staining were scored by the researcher blinded
to sample identity according to intensity of staining. yH2AX-positive cells were defined as having five or more
foci within the nucleus. Representative images for each genotype are shown. Scoring of all markers indicated
no differences between genotypes (data not shown).
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Figure 2-5. Gross pathology metrics. Animals were aged for 6 months with no manipulation.
Body, spleen and thymus weights were measured at necropsy. (A) Body weights do not differ
among genotypes studied. (B, C) Spleen (B) and thymus (C) weights relative to body weight
are significantly decreased in Rag2' animals. Bar height indicates median, error bars
indicate interquartile range. Student's t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
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Chapter 3
Exploring the Mutagenic Consequences of Intestinal Inflammation and
DNA Damage
3.1 Abstract
Inflammation is a major risk factor for many types of cancers, particularly colorectal. Intestinal
inflammation can arise from pathogenic infection or in the form of inflammatory diseases, such
as Crohn's disease or ulcerative colitis (UC). To expand upon our understanding of how
inflammation promotes mutations and cancer, we analyzed two model systems. First, we treated
Rag2-'~ mice with Helicobacter hepaticus, a pathogenic strain of bacteria that causes colonic
inflammation and cancer. Second, we utilized the ApcMin/ mouse model of colon cancer and
treated animals with dextran sodium sulfate (DSS) in drinking water to induce colitis and/or with
azoxymethane (AOM) to induce DNA damage. The results of these experiments suggest that
inflammation does not strongly induce de novo mutagenesis, but increases the total mutation
burden, likely due to heightened proliferation. Together, these studies indicate that inflammation
does not produce a significant amount of de novo sequence rearrangements, but it is a potent
promoter of cancer. However, inflammation does promote the overall burden of mutant cells by
increased proliferation, which increases the potential for mutant cells to acquire progressively
more mutations leading to cancer. Our experiments further suggest that DNA damage in colon
stem cells causes preferential apoptosis rather than mutation resulting in a decrease in
recombinant crypt foci, though this mechanism has not yet been verified. Thus, we conclude that
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inflammation promotes cancer, at least in part, through elevated proliferation, which enables
cells to accumulate and propagate mutations.
3.2 Introduction
Chronic intestinal inflammation is the single greatest risk factor for non-hereditary colorectal
cancer [1, 2], making the intestine a prime model tissue for studying inflammation-associated
carcinogenesis. Intestinal inflammation can arise from a variety of sources, such as pathogenic
infection, weak mucosal barrier function, or autoimmunity.
As a model of pathogen-induced inflammation, we selected Helicobacter hepaticus. H
hepaticus bacteria release cytolethal distending toxin (CDT), a holotoxin comprised of the
subunits CdtA, CdtB, and CdtC [3]. CdtA and CdtC form a heterodimer that enable translocation
of the catalytically active CdtB into the host cytoplasm [4]. CdtB is a DNase-I-family nuclease
that causes double strand breaks [5] and subsequent cell cycle arrest and apoptosis [6]. The DNA
damage response induced by CDT is similar to that of ionizing radiation, mediated by ATM and
causing cell cycle arrest at the G2/M and Gl/S checkpoints [7, 8]. Since CDT is the only known
virulence factor for H hepaticus [9], and since the host cellular responses closely mirror those of
DSB-induced cell cycle arrest and apoptosis [8], the production of DNA double strand breaks by
CDT is likely a major source of its pathogenicity.
While H hepaticus is known to induce inflammation, DNA damage and apoptosis, the
potential for H hepaticus to induce mutations has not been studied. To determine whether H
hepaticus infection can contribute to mutagenesis, we utilized RaDR;Rag2- mice, which lack a
functional adaptive immune system and sustain a stable inflammatory infection from H
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hepaticus [10]. Since many human pathogens also produce CDT [7, 8, 11], humans likely also
experience inflammation- and toxin-induced DNA damage simultaneously. Thus, this model
system allowed us to interrogate mutagenicity from two important and physiologically relevant
sources with a single agent. Surprisingly, however, while H hepaticus produced evident
inflammation for several months, we did not observe a difference in sequence rearrangement
mutations.
We also evaluated mutagenicity arising from several widely used and well-characterized
models of colon cancer. We exposed ApcMin/+ (Min) mice with two chemical treatments, dextran
sodium sulfate in drinking water and azoxymethane injection, which are used to model colitis-
associated and sporadic colon cancer, respectively.
Min mice have been used to study intestinal carcinogenesis for decades [12]. They
contain an inactivating point mutation in the tumor suppressor Apc, which results in spontaneous
intestinal tumorigenesis within the first two months of life. The Min phenotype also includes
elevated metrics of systemic inflammation, splenomegaly, thymic involution, and
lymphodepletion [13, 14]. Germline mutations in the human APC gene result in familial
adenomatous polyposis (FAP) [15], an inherited disorder resulting in spontaneous development
of adenomatous polyps in the colon. Like Min mice, FAP polyps start out benign but can
progress to malignancy. Mutations in APC are also a rate-limiting step in the progression of
sporadic cancer [16], and indeed APC has been found to be mutated in over 80% of all human
colon cancers [17]. Since inflammation is known to play an important role in the progression of
Min mouse tumors [18-20], we utilized this model as the basis of our second set of experiments.
Another widely used model of carcinogenic intestinal inflammation is dextran sodium
sulfate (DSS) dissolved in drinking water. DSS in drinking water has been used as a model of
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acute and chronic colitis for decades [21]. DSS is a detergent that produces nanovesicles with
medium chain fatty acids, which disrupt the mucosal surface of the colon epithelium and
increase permeability, causing inflammation [22]. Many DSS treatment regimens have been
designed for use in murine models to simulate varying degrees and kinetics of human colitis
[23]. Generally, 2-5% DSS w/v is dissolved in drinking water and provided to animals for 5-7
days. Multiple bouts of colitis can be simulated by providing DSS water for several days
followed by intervals of normal drinking water. Min mice treated with DSS water were found to
develop more numerous and severe intestinal polyps than those receiving normal water [24],
further supporting the supposition that inflammation contributes to progression of Min tumors.
DSS is frequently used in combination with the chemical mutagen azoxymethane
(AOM). AOM is delivered via intraperitoneal injection and gets metabolized in the liver and
colon by CYP2E1 [25] to produce the reactive methyldiazonium ion, which can then alkylate
DNA bases [26]. Typically, when AOM is used in combination with DSS, the AOM is delivered
first to induce purported initiating mutations, and then the colitis induced by DSS promotes
accelerated proliferation and progressive accumulation of further mutations to produce cancer.
Importantly, while AOM is primarily considered a mutation-initiating agent, it may also
contribute to tumor promotion [27]. Further, there is evidence that tumorigenesis from AOM can
be mitigated by blocking inflammation [28], indicating that inflammation is important to the
progression from AOM-initiation to neoplastic growth.
A key finding from the Engelward lab shows that when DNA damage occurs during
heightened proliferation, mutagenesis synergistically increases [29, 30]. We incorporated this
observation into our experimental design, electing to inject Min mice with AOM during the
regenerative proliferation following DSS treatment. Since every cell in the Min mouse is
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heterozygous for an inactivating mutation in the Apc gene, all Min cells can be thought of as
"initiated" in the multistep model of cancer progression, so in this experiment we are
investigating how inflammation (DSS) and DNA damage (AOM) contribute to cancer
promotion.
The results of our experiments treating Min mice with DSS and AOM show several
surprising features. First, we found that DSS-induced inflammation potently increases colon
tumorigenesis as well as a corresponding increase in the overall burden of recombinant cells. We
also discovered that, counterintuitively, AOM treatment reduced the density of recombinant
colon crypt foci. AOM treatment increased tumor multiplicity in the small intestine but not the
colon. Finally, analyzing mutations in extra-intestinal tissues revealed that AOM and/or DSS
treatment may promote sequence rearrangement mutations in off-target tissues.
3.3 Materials and Methods
3.3.1 Rag2-'- animals for H. hepaticus treatment
Experimental RADR/'R ;gpt-J;Rag2-- (RGR) animals were created by crossing
Rag2-1- (129S6/SvEvTac-Rag21 Fia) [10] with RADRNR;gpt- animals also on the 129
background. Litters were split into infection and control cohorts with equal numbers of males
and females in each group. Uninfected mice were housed in a barrier facility free of known
murine Helicobacter species, viruses, Salmonella species, Citrobacter rodentuim, ecto- and
endoparasites.
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3.3.2. H. hepaticus treatment
H hepaticus (strain 3B 1, no. 51449; ATCC, Rockville, MD) was grown as described under
microaerobic conditions on blood agar plates and collected into sterile freeze media [10]. A total
of 41 experimental animals 6-8 weeks of age received 0.2 ml freezing medium (n=19) or freshly
prepared H hepaticus inoculum (total organism dose of 108 CFU, n=22) via gastric gavage every
other day for 3 doses. Two weeks later, the mice received a second round of 3 doses every other
day for a total of 6 doses. Prior to dosing, all H hepaticus samples were examined via gram stain
to ensure >85% of the bacteria were in the spirochete form (virulent form). Tissues were
harvested at 10 weeks post infection utilizing standard necropsy procedures.
3.3.3 H. hepaticus PCR
Feces were collected from each animal during necropsy to confirm presence of H hepaticus.
DNA was extracted from feces using the QIAamp DNA Stool Mini Kit. PCR was run using
primers specific to the H hepaticus strain [31].
3.3.4 Histopathology
Formalin-fixed tissues were embedded in paraffin, cut in 5 ptm sections, and stained with
hematoxylin and eosin. Sections were scored by a pathologist blinded to sample identity.
3.3.5 Apc M"'* animals and AOM and DSS treatments
Experimental C57 RADR R;gpt-;ApM'n/+ (RMin) animals were created by crossing
RADR RR;gpt-J animals with C57B1/6J Apc Mi"+ mice donated by Dr. Susan Erdman. Animals
were bred and maintained in an AAALAC-accredited barrier facility free of known murine
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Helicobacter species, viruses, Salmonella species, Citrobacter rodentium, ecto- and
endoparasites. At six weeks of age, experimental animals were transferred to a hazardous
materials containment facility at least two days prior to the beginning of treatment.
DSS (MP Biomedicals, 35,000-50,000 kDa) was dissolved in water obtained from the
mouse colony at 1% w/v. DSS-treated animals were supplied with this water for seven days, at
which point they resumed normal drinking water.
AOM (Sigma-Aldrich) was diluted to 10 mg/mL in sterile PBS and stored in aliquots at -
20'C. On the day of treatment, AOM was diluted to 1 mg/mL in sterile PBS and sterile filtered
with a 0.2 pm filter just prior to dosing. Each animal was weighed and the appropriate volume of
AOM was calculated such that the animal would receive a single i.p. injection of 4 mg AOM per
kg body weight. Sham-treated animals were weighed and injected with an equivalent volume of
sterile PBS.
Following pilot studies to determine appropriate dosing, three treatment regimens were
performed. The first, main experiment entailed mice at 6 weeks of age to be split evenly between
control, DSS, AOM, and DSS+AOM treatment regimens. All animals were housed in a
hazardous material containment facility for the duration of the experiment regardless of
treatment. Animals received either 1% DSS or normal drinking water for seven days, then all
animals were given normal water. On day 10 (three days after return to normal water), animals
were dosed with an i.p. injection of either 4 mg/kg AOM or sterile PBS. Animals were
necropsied on days 21-23. The second experiment was set up identically, but with no control
group, and animals were necropsied on day 12 (two days after AOM). The final experimental
cohort received 4 mg/kg AOM i.p. injection on the first day, then 1% DSS water from days 5-12,
and were necropsied on day 21.
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Animals were monitored daily for signs of distress and morbidity and weighed at least
every other day. Animals that dropped below 80% of their initial body weight were humanely
euthanized. At the end of the experiment, mice were euthanized by CO 2 according to AVMA
guidelines and necropsied with standard procedures.
3.3.6 DSS Pilot Ki67 Immunofluorescence
Formalin-fixed tissue sections were embedded in paraffin and cut in 5 pim sections. Slides
stained for immunofluorescence were first deparaffinized with three five-minute washes in
xylenes, two five-minute washes in 100% ethanol, and 10-minute washes each in 95% ethanol,
90% ethanol, and 70% ethanol. Slides were washed twice in PBS, then boiled in Dako citric acid
antigen retrieval buffer (S1700, Agilent Technologies, Santa Clara, CA) for 30 min. After
cooling, slides were washed twice in diH20 and tissue sections were circled with hydrophobic
marker. Sections were blocked for one hour with 5% BSA + 0.3% Triton in PBST at room temp.
All antibodies were diluted in 1% BSA + 0.3% Triton in PBST, and sections were stained
overnight at 4'C. Slides were then washed three times for five minutes each in PBST and
incubated with the appropriate secondary antibody for one hour at room temperature. Slides were
then washed five times in PBST for five minutes each. Finally, a drop of DAPI with ProLongTM
AntiFade reagent (Invitrogen) was placed on the section, and a cover slip was laid overtop and
sealed with clear nail polish. Anti-Ki67 antibody was Abcam abi 5580, rabbit origin, and the
secondary antibody was Alexa Fluor 647 (goat anti-rabbit).
Slides from each intestine segment were stained in parallel and imaged on the same day
under identical conditions. The researcher was blinded to sample identity for scoring. Images
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were evaluated in Photoshop CS6, and the number of Ki67+ cells in complete crypt cross
sections were counted and recorded. Each crypt served as a single data point.
3.3.7 RaDR Necropsy and Tissue Imaging
Animals were euthanized with CO 2 according to AVMA guidelines. Tissues were excised and
held on ice in tubes containing PBS (mammary) or PBS with 0.01% trypsin inhibitor (T9008
Sigma-Aldrich or P-1540 Westnet Inc) (pancreas, liver, intestines) until use. The entire colon
was excised (cecum to anus), and the small intestine was divided roughly into thirds, such that
the duodenum (proximal, attached to stomach), jejunum (middle section), and ileum (distal,
attached to cecum) were approximately equal lengths. Intestines were cut open on one side and
the lumen was rinsed of fecal matter before placing in PBS + trypsin inhibitor. Mammary,
pancreas, liver and intestine tissues were compressed to 0.5 mm between coverslips and imaged
for EGFP under the Ix objective with the FITC filter of a Nikon 80i fluorescent microscope.
3.3.8 Quantifying RaDR Mutagenesis
RaDR transgenic mice develop fluorescent (EGFP+) cells following a sequence rearrangement
mutation at the transgenic construct. Mutagenesis can be quantified in a variety of ways with
varying biological significance. This data is collected either by imaging the whole tissue on a
fluorescence microscope or cell sorting by flow cytometry.
Foci counting
Imaging of a RaDR tissue allows enumeration of individual foci, which correspond to single
mutation events. Cells that have acquired the RaDR mutation may clonally expand, leading to
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various sizes of foci, and so it is often of interest how many mutation events occurred in the
tissue instead of, or in addition to, the total proportion of mutated cells. In collaboration with Dr.
Dushan Wadduwage of Peter So's laboratory, we have developed a MATLAB program that
enumerates the total number of foci in the tissue and measures the area of the tissue, providing
results as foci/cm2. This is the preferred method for quantifying de novo recombination events in
pancreas and liver tissues.
Crypt foci counting
Intestines have regular, distinct architecture that enables identification of mutations in somatic
stem cells. Intestine epithelium consists of pore-like divots into the mucosa called crypts, and the
small intestine also contains fingerlike projections into the lumen, called villi. At the base of
each crypt are one or more somatic stem cells, which give rise to the proliferative transit cells
that comprise the length of the crypt and, in the small intestine, the villi surface. The continual
proliferation of stem and transit cells enables continual renewal of crypt (and villus) epithelia.
Transit cells are eventually sloughed off into the lumen, and stem cells produce complete
epithelial turnover within 3-5 days [32]. In a RaDR animal, mutations in crypt stem cells are
visible as large, bright, roughly circular foci that can be distinguished from the smaller, dimmer
and/or irregularly shaped foci of mutated transit cells. The foci that we believe to be converted
crypts are, on average, lOx brighter and 6x larger than foci that appear to be single cells. Since
somatic stem cells persist for years, if not the animal's lifetime, whereas transit cells are
sloughed off within 5 days, it is of great interest to quantify recombinant stem cell foci rather
than all foci. To this end, we have collaborated with Dr. Wadduwage to develop a modified
version of the MATLAB foci counting program that allows the user to "train" the program which
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foci to count based on size, shape and intensity, enabling quantification of mutated stem cells in
the tissue normalized to tissue area in tumor-free tissue (see Fig 3-lB for example).
Percent area mutated
When intestinal tumors develop, the regular architecture of the intestine becomes disrupted, and
somatic stem cells are no longer distinguishable and cannot be quantified. For this reason, we
have developed a method to approximate the area of the tissue that can be classified as EGFP+.
By defining conservative thresholds for pixel intensity in ImageJ, we quantify the area of tissue
that is brightly fluorescent and thus have a rough measure for the total mutation burden in the
tissue (see Fig 3-1C for example). These results are given as the percent area of tissue that is
fluorescent.
Flow cytometry
Flow cytometric sorting allows quantification of the overall proportion of mutated cells in the
tissue. This method is most useful for tissues that are too thick for imaging (e.g., spleen) or have
very small cells with irregular internal structures that make focus counting intractable (e.g.,
thymus, lung). Since flow cytometry requires disaggregation of the tissue, it is not possible to
distinguish between mutation events and clonal expansion of mutated cells, nor is it possible to
perform additional assays, making this method appropriate only for tissues that cannot be
analyzed with the methods described below.
117
3.3.9 Tumor Quantitation
Following RaDR imaging, intestine segments were laid flat on bibulous paper and cut in half
longitudinally. Half the tissue was fixed in 10% formalin for tumor counting, and half was snap-
frozen in liquid nitrogen for Gpt assay (see below). After several days, the formalin was
discarded and replaced with 100% ethanol for 24 hours. The ethanol was then discarded and
replaced with 70% ethanol. To count tumors, intestine segments were carefully removed from
the bibulous paper cassettes and placed on a stereoscopic lOx microscope. The approximate sizes
and locations of tumors within each segment were recorded on paper. Tumors counts are
represented by Tukey boxplots, wherein the boxes represent quartiles of data and whiskers
represent the data lying within 1.5*IQR (interquartile range). Data points lying outside 1.5*IQR
are represented as dots.
3.3.10 Gpt point mutation assay
The Gpt assay was performed as described previously [33, 34]. DNA was extracted from snap-
frozen colon and ileum samples using the RecoverEase DNA Isolation Kit (Agilent
Technologies, Santa Clara, CA). In order to ensure a sufficiently large volume of high molecular
weight DNA with each preparation, two samples of colon (or ileum) tissue were combined in the
mortar before grinding the tissues, so each data point represents the DNA of two animals. The
same individuals were paired for both colon and ileum sample sets.
DNA was packaged with X-EG10 phage extracts, which were prepared in-house. Empty
phage head extracts were prepared by culturing NM759 E. coli in NZY broth at 32'C, heat-
shocking the culture at 45'C for 15 min, then re-expanding at 38'C. Bacteria were then pelleted
at 1,800 x g and resuspended in a buffer containing 20 mM TrisCl, 10 mM EDTA, and 0.035%
118
P-mercaptoethanol. The suspension was sonicated 12x in three-second bursts on a Misonix
Sonicator 3000 at power level 4, between which the suspension was held on ice for 25-30
seconds. The suspension was then pelleted at 6,000 x g, supernatants collected and combined
with a packaging buffer containing 6 mM TrisCl, 50 mM Spermidine-HCl, 50 mM Putrescine-
HCl, 20 mM MgCl2, 30 mM ATP, and 0.021% P-mercaptoethanol. Aliquots were then snap
frozen in liquid nitrogen.
Phage "pre-head" complexes were prepared by culturing BHB2866 E coli in NZY broth
at 32'C, heat-shocking the culture at 45'C for 15 min, then re-expanding at 38'C. Bacteria were
then pelleted at 1,800 x g, resuspended in a 10% sucrose solution containing 50mM TrisCl, snap
frozen in 0.5 mL aliquots, and stored at -80'C. Frozen bacteria were later thawed on ice and
ultracentrifuged at 163,000 x g for three hours at 4'C. The supernatant was combined with
packaging buffer containing 6 mM TrisCl, 50 mM Spermidine-HCl, 50 mM Putrescine-HCl, 20
mM MgCl2, 30 mM ATP, and 0.02 1% P-mercaptoethanol, then snap-frozen in aliquots.
Each time DNA was packaged and the Gpt assay was performed, five samples were
processed: one from each treatment group, and one internal control. DNA was packaged by
combining thawed aliquots of both phage extracts with high molecular weight intestine DNA,
incubating at 32'C for 90 minutes, adding an additional set of thawed phage extracts for 90
minutes at 32'C, and finally halting the reaction by addition of a buffer and setting on ice.
Phage packaging efficiency was evaluated by infecting lysogenic MRA E. coli with
packaged phage and quantifying plaques. The titer of packaged Gpt DNA was quantified by
infecting YG6020 E. coli with packaged phage and selecting for chloramphenicol resistant
colonies, and the mutant fraction was determined by plating infected YG6020 F. coli on
chloramphenicol and 6-thioguanine selection plates.
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3.3.11 Statistical Analyses
RaDR foci were quantified as the number of foci per square centimeter of area (foci/cm2 ), and
RaDR flow cytometry measurements were given as % fluorescent* 106. Due to the fact that the
distribution of EGFP-positive cells in RaDR mice is non-normal across tissues and among
individuals, RaDR data sets were compared by Mann-Whitney U-test. It was not clear that tumor
multiplicity was normally distributed between individuals, and therefore tumor counts were also
compared by Mann-Whitney U-test. Body and tissue weights were compared by unpaired
Student's t-test. All statistical comparisons were calculated using GraphPad Prism 5.
3.4 Results
3.4.1 H. hepaticus infection causes inflammation but does not significantly alter
mutagenesis
We confirmed that H hepaticus-infected animals had retained the bacteria through the duration
of the experiment by collecting feces at necropsy, extracting DNA, and performing PCR (data
not shown). Histopathological evaluation confirmed that infected animals were experiencing
colonic inflammation (Fig 3-2). This experiment predated the development of the MATLAB foci
counting programs, and so initial quantification of RaDR foci was accomplished by manual
counting of blinded images. Despite being blind to sample identity, this method of quantifying
foci still risks user bias, so we subsequently re-analyzed images with the unbiased MATLAB
program. While manual enumeration of RaDR foci in the colon, liver and pancreas indicated a
slight but significant decrease in mutation frequency in infected animals (Fig 3-3, left panels), re-
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analysis by the MATLAB program showed no significant differences in mutagenicity due to H.
hepaticus infection (Fig 3-3, right panels).
Unfortunately, the RaDR image data was collected in under inconsistent exposure
conditions, and a single intensity threshold for estimating percent tissue fluorescence with
ImageJ could not be applied to all images in the data set. Therefore, we were unable to compare
the overall mutant burden in H hepaticus colons.
3.4.2 DSS recovery pilot to determine dosing schedule
A key observation from other recombination studies in the pancreas is that if DNA damage
occurs during a period of increased proliferation, sequence rearrangement mutations
synergistically increase compared to DNA damage or proliferation alone. Thus, we hypothesized
that if DNA damage from AOM occurs during the regenerative proliferation following DSS-
induced inflammation, we would similarly see a large increase in recombination.
Six 6-week old males were given 1% DSS in drinking water for 7 days, and then two
mice each were sacrificed on days 8, 10 and 12 (one, three and five days after return to normal
drinking water). Intestines were saved as swiss rolls in formalin, embedded in paraffin, and
sectioned for Ki67 immunofluorescence. Slides from D8, D10 and D12 were grouped by
intestine segment, stained in parallel for Ki67, and imaged on the same day. Three images per
slide were taken and filenames were blinded. Ki67+ nuclei were counted for each full crypt
cross-section in the field and recorded. Quantification indicated that colon crypts had a peak in
the number of proliferating cells on D10 (Fig 3-4A), and so this day was selected for AOM
treatment.
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Subsequently, six 6-week old animals (three of each sex, see Table 3-1) were sacrificed
as a day zero untreated control and intestines were again saved for immunostaining. Slides from
DO, D8, D10 and D12 were grouped by intestine segment, stained in parallel for Ki67, and
imaged on the same day. Four images per slide were taken and filenames were blinded. This
second quantification indicated that peak proliferation in colon crypts was on D12, but the
median on D12 (14 Ki67+ cells) was only two more than the median on DO (12 Ki67+ cells).
Thus, while the difference between DO and D12 is statistically significant, it is by only a small
amount.
We also stained and imaged one slide from each intestine segment for H&E
(representative images shown in Fig 3-4C). Colon polyps are visible in all DSS-treated samples
(Fig 3-4C, circles), but in all samples there also appear to be regions of relatively normal
physiology. Note that since we only counted Ki67+ cells in complete crypt cross-sections, we
necessarily excluded proliferating cells in tumors (which no longer have intact crypts).
3.4.3 Experimental treatments cause some morbidity
Based on pilot experiments, we treated animals according to the timeline shown in Figure 3-5A.
As RADRR;gpt-J;ApcMIn/+ (RMin) mice reached six weeks of age, they were divided between
Control, AOM, DSS and DSS+AOM treatment groups such that all treatments would be
performed in parallel. Each of the treatments produced some morbidity (Fig 3-5B), so as the
experiment progressed, animals were divided between groups to aim for similar numbers of
males and females with necropsy data (see Table 3-1). Data is not presented for animals
sacrificed before the end of the experiment because the primary objective was to analyze
accumulation of mutant cells, which requires that all animals are analyzed at the same timepoint.
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Animals that were able to tolerate treatments had fully recovered their body weight by the end of
the experiment (Fig 3-5C). DSS treatment caused significant loss of body weight after returning
to normal water (Fig 3-5C) and exacerbated Min splenomegaly (Fig 3-5D), both of which are
consistent with DSS causing severe inflammation [23]. AOM treatment produced a significant
drop in body weight the day after dosing (DI 1), but mice quickly recovered (Fig 3-5C).
3.4.4 DSS induces distal colon tumors and AOM induces ileum and duodenum tumors
DSS treatment produced a significant increase in tumors in animals' colons (Fig 3-6A). Notably,
DSS consistently caused densely packed tumors in the distal two-thirds of the colon, but the
proximal third of the colon rarely had any polyps. In contrast, AOM-treated animals developed
more polyps in the ileum and duodenum (Fig 3-6B, D). Neither treatment altered tumorigenesis
in the middle portion of the small intestine, the jejunum (Fig 3-6C).
3.4.5 DSS increases the total burden of recombinant cells
We analyzed intestinal mutations by several different methods for different perspectives of
mutagenicity. First, we quantified the total area of the tissue above a defined threshold pixel
intensity as an approximation of the total burden of recombinant cells in the tissue (see Materials
and Methods, Quantifying RaDR mutagenesis, Percent area mutated). By this metric, we
observed a significant increase in the overall burden of mutant cells in colons that had received
DSS treatment (Fig 3-7A). We also observed a larger overall mutant burden in colons and ilea of
animals that received both DSS and AOM compared to animals that received AOM alone (Fig 3-
7A, B).
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Importantly, the increase in DSS-treated colons' overall mutant burden was driven in
large part by tumors. Tumors can acquire the RaDR rearrangement mutation at any point during
development, and thus tumors may be partially or fully fluorescent. For example, the colon
shown in Figure 3-1A received DSS treatment and thus has densely packed tumors in the distal
two-thirds of the tissue (white box). Analyzing this tissue for total mutant burden indicates that
4.3% of the tissue fluoresces above the pixel intensity threshold, the vast majority of which
results from the large fluorescent tumors near the middle of the tissue (Fig 3-1 C). More
commonly, tumors have patches of fluorescence, and the total area that exceeds the threshold
intensity is less than 1% of the tissue.
Interestingly, despite the fact that AOM induced tumors in animals' ilea and jejuna,
AOM did not increase the total burden of recombinant cells in any intestine segment.
3.4.6 AOM reduces frequency of somatic stem cell recombination
Since tumors were almost exclusively present in the distal two-thirds of the colon, macroscopic
folds of tissue characterize the proximal third of the colon, and large tumors are often visible in
RaDR tissue images, we were able to identify a consistently tumor-free region in all colon
samples to analyze for recombinant crypt foci (Fig 3-1B). We analyzed the same region in every
sample by the crypt foci counting program (see Materials and Methods, Quantifying RaDR
mutagenesis, Crypt foci counting). Surprisingly, we found that animals treated with AOM alone
had a significantly lower frequency of recombinant crypt foci (Fig 3-8A).
We also quantified mutant crypts in ileum tissue by excluding any tumors that were
visible in the RaDR image in the counting program. These results suggest that AOM-treated ilea
contained a lower frequency of converted crypts compared to animals that received both AOM
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and DSS (Fig 3-8B). However, the crypt-counting program performs less reliably in
distinguishing small intestine crypts compared to colon because the small intestine villi create
more variability in the appearance of foci.
3.4.7 DSS+AOM combination treatment may increase point mutations
To provide a more comprehensive analysis of mutations from DSS and AOM treatments, we
performed the Gpt assay for point mutations. Animals treated with the combination of DSS and
AOM were found to have a larger mutant fraction in the colon compared to other groups (Fig 3-
9A), but there were no significant differences in point mutations in animals' ilea (Fig 3-9B). Due
to great variability in the data from this assay, we do not draw firm conclusions from the data
collected and will perform replicates to improve confidence.
3.4.8 Early analysis shows no AOM-induced recombination, but rapid induction of tumors
by DSS
We hypothesized that AOM may produce RaDR mutations in intestinal transit cells that are
sloughed off before necropsy. To determine whether this was the case, another cohort of animals
were given AOM, DSS and DSS+AOM treatments as described in Figure 3-4A, but all animals
were necropsied on day 12, two days after AOM dosing (see Table 3.1). This would provide
sufficient time for the AOM to be metabolized and react with DNA, and cells could undergo a
full replication cycle to develop the RaDR mutation, but transit cells would not yet be sloughed
off.
We did not observe significant induction of mutations at this early timepoint in any
intestine segment (Fig 3-10A). One noteworthy observation is that DSS treatment causes colon
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tumors within five days of returning to normal water (Fig 3-1 OB), which is consistent with other
studies of ApcMi"'/ animals treated with DSS [24].
3.4.9 AOM treatment before DSS does not significantly increase mutagenesis
The standard treatment schedule for AOM in combination with DSS is to deliver the AOM first,
followed several days later by DSS in drinking water. Therefore, we wished to compare our
treatment regimen, where AOM was timed to coincide with proliferation after DSS, to the more
traditional model of dosing AOM first. We treated animals as shown in Figure 3-1 IA (see Tables
3.1 and 3.2 for cohort composition). Animals in this experiment experienced more severe body
weight loss and morbidity (Fig 3-11 B, C), though it is important to note that a larger number of
females were allocated to this experiment than other cohorts (Table 3.1), and females are more
sensitive to toxicity from DSS.
We quantified intestinal mutagenicity in terms of total recombinant cell burden as well as
crypt foci in non-tumorous tissue. Surprisingly, animals treated with AOM prior to DSS
developed fewer recombinant colon crypts as well as a lower proportion of fluorescent tissue in
all intestine segments compared to the groups in the main experiment (Fig 3-12A, B. Data for
DO, Ctrl, AOM, DSS and DSS+AOM shown for comparison). Indeed, the frequency of
converted crypts and overall mutant burden in the AOM-then-DSS animals are much more
similar to the animals analyzed for the Day 12 early timepoint (Fig. 3-12C, D. DO and D12 data
shown for comparison). It is important to note that D21, D12 and AOM-then-DSS experiments
were not performed in parallel (see Table 3-1). Therefore, comparisons are limited to qualitative
descriptions and no firm conclusions can be drawn.
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3.4.10 Off-target mutagenesis
In addition to analyses of mutations in intestine tissue, we also collected RaDR data from liver,
pancreas, spleen, and thymus tissues to see if DSS or AOM, commonly considered colon-
specific treatments, produce mutations in other tissues. There was a small but significant increase
in the number of foci in the liver and pancreas of mice that received the combination of DSS
followed by AOM (Fig 3-13A, B). The spleen and thymus also appear to be susceptible to
increased mutagenesis from AOM treatment (Fig 3-13C, D), but these results are not statistically
different from control.
3.5 Discussion
The experiments described in this chapter yielded many unexpected but enlightening results.
Although we did not observe an increase in recombination frequency due to inflammation or
DNA damage, we uncovered circumstances that increase recombinant cell burden and decrease
recombinant cell frequency.
The first experiments described here, dosing Rag2' mice with H. hepaticus, first indicated that
infection slightly decreases recombination frequency in the liver and colon, but subsequent
image analysis by MATLAB did not show statistically significant difference in results (Fig 3-2).
The fact that colon and liver both showed the same trend in decreased recombination frequency
is noteworthy because H hepaticus is known to cause both colitis and hepatitis in mice, so both
tissues with ambiguously fewer foci were targets of the pathogen [35, 36]. Importantly, however,
H. hepaticus combines both DNA damage and inflammation into a single treatment, and tumors
had not yet begun to develop, so we designed an experiment separating the variables of DNA
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damage (AOM) and inflammation (DSS) and applied it to a model of heritable colon cancer.
Interestingly, treatment with our model DNA damaging agent AOM also resulted in fewer
recombinant crypt foci.
Cairns' immortal strand hypothesis offers one explanation for how both H. hepaticus
infection and AOM treatment could reduce recombinant crypt foci frequency. Cairns posits that
somatic stem cells protect their original DNA strands by selective segregation during mitosis,
and that irreversible damage causes the cell to undergo apoptosis as a protective mechanism
against mutations [37]. Indeed, a number of studies have evidence supporting a model of
selective chromatid segregation [38, 39]. This hypothesis is further supported by studies showing
that CDT causes cell cycle arrest and apoptosis via the ATM-dependent intrinsic pathway [7, 9].
There are two important inconsistencies between the immortal strand hypothesis and
results of our experiments. First, Cairns suggests that somatic stem cells should be deficient in
recombinatorial repair to protect the "immortal strands" from exchange, but the fact that we
observe fully fluorescent crypts suggests that not all recombination is inhibited {Cairns 2006}.
Second, Cairns posits that dead stem cells are replaced by dedifferentiated daughter cells, but
that would entail a RaDR stem cell being replaced with a daughter that also has the RaDR
mutation, leaving recombinant crypt frequency unchanged. More work is necessary to determine
what happens to colonic stem cells exposed to DNA damage and how the tissue responds. Our
data support a model wherein colonic stem cells undergo mutagenic recombination sporadically
and crypt foci accumulate with age, and separately, the induction of DNA damage causes crypt
stem cells to die without replacement by dedifferentiated daughters.
Complications with the bacteria may have confounded the results of the H. hepaticus
study. For instance, H. hepaticus virulence varies between strains [40], and CDT activity is
128
necessary for cytotoxicity and DNA damage response activation [9, 36]. If, during culture or
passaging of the bacteria, the strain mutated to lose virulence potency, the mutagenic
consequences of the CDT toxin may have been diminished. Furthermore, we have seen that the
timing of DNA damage in relation to proliferation is a key modulator of recombination
frequency, but in this model we know little regarding the kinetics of proliferation and bacteria
activity during the 3 months of infection. The gut may enact protective mechanisms, such as
modified proliferation kinetics, during infection that cannot be identified at a single late
timepoint.
We designed our second set of experiments, treating ApcMi"/+ (Min) mice with dextran
sodium sulfate (DSS) and/or azoxymethane (AOM) with the objective of greater control over
experimental variables. A crucial aspect of our experimental design relied on determining when
regenerative proliferation peaks following DSS-induced inflammation, having observed synergy
when DNA damage occurs during proliferation in the pancreas [29, 30]. We quantified the
number of proliferating cells in crypts of each intestine segment one (D8), three (D10) and five
(D12) days following the return to normal water after seven days of DSS, and results indicated
that proliferation peaked around D10 or D12 (Fig 3-3), which is consistent with other studies
[41]. Notably, however, the median numbers of proliferating cells at these times were only one
or two increased from untreated animals, so while the increase in proliferation was statistically
significant, it was not a large difference. The low variability in colon proliferation activity
suggests the colon is less susceptible to perturbations in proliferation as a result of inflammation.
Our two experimental treatments both induced tumors in Min mice, but in different
locations. DSS treatment typically produces tumors in the distal colon [23], which is consistent
with our results here. Interestingly, however, AOM induced tumors in the proximal and distal
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small intestine (duodenum and ileum, respectively). Although AOM is often considered a colon-
specific treatment, several studies have shown that it produces methylation adducts in the liver
and small intestine, provided the tissue expresses CYP2El [26]. The expression of P450
enzymes has not been characterized along the Min small intestine, but P450 expression is known
to vary along the gastrointestinal tract [42], so perhaps differential CYP2E1 expression in the
duodenum and/or ileum increased the mutagenicity of AOM in those segments.
Proliferation kinetics may also factor into AOM carcinogenicity. Min mice spontaneously
develop the majority of polyps in the ileum, suggesting that Wnt dysregulation and
hyperproliferation are most pronounced in the ileum, and therefore most susceptible to DNA
damage-induced mutations. It is likely that CYP2E1 activity and proliferation kinetics both play
a role in AOM tumorigenesis.
While none of these experimental treatments increased recombination frequency in the
intestines, we did observe a significant increase in the total burden of recombinant cells in
tumorous colon tissue. The most likely mechanism for this observation is that hyperproliferation
and progressive genomic instability in tumors produced many opportunities for cells to acquire
the RaDR mutation. Indeed, we observed tumors that appear to have acquired the RaDR
mutation early on, producing fully or near-fully fluorescent polyps (Fig 3-7). There also appears
to be a trend of increasing recombinant cell burden with time post-DSS exposure (e.g. early
analysis at D12 and AOM-then-DSS; see Fig 3-12). This result is not surprising, given that we
have already shown previously that the majority of RaDR mutant cells in normal tissue derive
from clonal expansion of rare recombination events rather than de novo mutations [43, 44].
Finally, these experiments permitted several novel analyses. First, we multiplexed our
mutation analyses by performing the Gpt assay on tissue that had been analyzed for sequence
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rearrangement mutations. By adding replicates of this assay to our data set, we will be able to
confidently comment on multiple types of mutagenicity resulting from AOM and DSS
exposures. Additionally, the RaDR mouse permits efficient, cost-effective analysis of off-target
tissues as well. Whereas typical laborious mutation assays require careful selection of samples in
the interest of time and money, little additional effort is required to analyze many tissues for
RaDR mutations. Using the RaDR mouse, we were able to incorporate mutation analyses of
many extra-intestinal tissues, including the pancreas, liver, spleen and thymus (Fig 3-13). While
we did not anticipate any significant differences in mutations in these off-target tissues, we were
intrigued to discover that DSS+AOM increased mutation frequencies in the liver and pancreas,
and surprised to discover that AOM-treated lymphoid organs are prone to extremely high
proportions of recombinant cells.
In conclusion, the experiments described in this chapter support a model whereby DNA
damage in intestinal stem cells promotes apoptosis rather than mutations, and inflammation
increases the total burden of mutated cells by clonal expansion.
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Figure 3-1. Sample quantifications of RaDR mutagenesis. (A) Original
colon RaDR image. White box indicates tumor-filled area. (B) Tissue
that does not contain tumors can be analyzed for converted crypt foci.
(C) Total mutant burden (percent area fluorescent). Note that large red
regions correspond to fully (or near-fully) fluorescent tumors.
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Figure 3-2. H-. heirpaticus infection causes colonic inflammation in Rag2t4
mice.
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Table 3-1 Cohort compositions
Males Females Total
Cohort Timing
treated analyzed treated analyzed treated analyzed
DSS recovery pilot 6 2/day 6 6 Separate
DO 3 3 3 3 6 6 Separate
Ctrl 10 10 6 6 16 16
AOM 11 10 7 7 18 17
Parallel
DSS 11 10 8 6 19 16
DSS+AOM 12 9 11 6 23 15
D12 AOM 4 4 1 1 5 5
D12 DSS 5 5 1 1 6 6 Parallel
D12 DSS+AOM 4 4 4 3 8 7
AOM-then-DSS 5 3 8 2 13 5 Separate
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Figure 3-5. Experimental design. (A)
Treatment schedule. (B) Kaplan-Meier
survival curve. (C) Animal body weight
change over the course of the
experiment. (D) Ratio of spleen weight
to body weight at necropsy. Unpaired
Student's t-test, *p < 0.05, **p < 0.01,
***p < 0.001, Op < 0.0001.
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Chapter 4
Increased Aag Expression Reduces Spontaneous Sequence
Rearrangement Mutations
4.1 Abstract
In order to repair the many types of DNA damage cells may encounter, a network of repair
pathways has evolved. One of the most important repair pathways for coping with DNA damage
from inflammation is Base Excision Repair (BER), but the intermediates of the BER pathway
include abasic sites and strand breaks, which are essentially DNA lesions as well. Importantly,
BER intermediates can cause replication forks to break down, and the only way to accurately
restore a broken replication fork is with homologous recombination (HR). While HR is mostly
error free, it can produce large-scale mutations such as insertions, deletions, translocations and
loss of heterozygosity. Thus, BER intermediates during replication can lead to large-scale
mutations. To illustrate the relationship between BER intermediates and HR-driven mutations,
we crossed animals with increased expression of a BER glycosylase with our RaDR mice and
quantified the accumulation of mutations across 10 tissue types. Interestingly, we found that
AagTg animals developed fewer RaDR mutations than AagWT, with tissue- and sex-dependent
variability. Of the tissues studied, we observed significantly lower frequencies of de novo HR
events in AagTg pancreata and colons, and lower proportions of mutated cells in the spleen and
lungs. Separating the data by animal sex further revealed that the only tissue where AagWT and
AagTg females show a significant difference is the pancreas, whereas male animals had
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significant differences in the colon, spleen, heart and kidney. Quantifying abasic sites in colon
DNA did not reveal a pattern of increased BER intermediates in AagTg animals. Finally,
Spearman correlation analyses revealed that mutation frequency (measured by foci) may be
correlated between tissues within an animal, but overall mutant proportion (measured by flow
cytometry) is not.
4.2 Introduction
In general, Base Excision Repair (BER) DNA repair pathway deals with single-base lesions that
do not significantly distort the DNA helix. The first step of BER is removal of the damaged base
by one of several DNA glycosylases. The second step is to cut the backbone, which can be
accomplished by bifunctional glycosylases or AP endonuclease-1 (APE1). The two ends of the
single strand break (SSB) must then be processed to produce a 3'OH (with APE1, Polp, or
PNKP) capable of extension and a 5'PO4 (with Polp or PNKP) capable of ligation. The gap is
filled in with Polo, and ligase seals the nick to complete the process. The elements of BER
downstream of the glycosylase can also contribute to repair of SSBs.
Importantly, every intermediate of the BER pathway contains a potentially toxic lesion:
either an abasic site or a strand break. Normally, the cell is able to complete BER without
toxicity, but this is not always the case. If there is a large amount of damage, there may be
simply too few of the molecules necessary for repair, such as Polo, leading to an accumulation of
cytotoxic lesions and subsequent apoptosis. Accumulation of BER intermediates can also result
in bioenergetic collapse and necrosis due to excessive PARylation of SSBs. Alternatively, if a
replication fork encounters a BER intermediate, the fork may break down, creating a one-ended
151
double strand break (DSB). Thus, while BER is essential for repairing DNA damage during
inflammation, this pathway can sometimes do more harm than good by generating toxic
intermediates.
Broken replication forks produce toxic DSBs, which require homologous recombination
for accurate restoration. Since HR utilizes a homologous region of DNA as a template, this
process is mostly error-free as long as the cell identifies the correct sequence in the sister
chromatid. However, identification of homology in the homologous chromosome rather than the
sister chromatid can lead to loss of heterozygosity, a significant source of tumor suppressor
inactivation [1, 2]. Furthermore, a significant portion of the genome has been identified as
repetitive or repeat-derived: nearly 10% of the genome consists of Alu repeats [3, 4], and a
recent analysis estimates 2/3 of the genome consists of repetitive elements [5]. Thus, there are
many opportunities for HR to identify a homologous sequence in the wrong location. Aberrant
HR can lead to translocations, deletions, insertions, or sequence rearrangements [6-11].
In order to quantify aberrant HR in situ, the Engelward lab developed the RaDR mouse,
wherein improper HR within the ubiquitously expressed transgene generates a fluorescent
product. Briefly, these transgenic animals contain a direct repeat of truncated EGFP sequences at
the Rosa26 locus. The 5' copy of EGFP is truncated within the 5' EGFP coding region, and the
3' copy is likewise truncated at the 3' end of the gene. If a double strand break occurs in one of
these repeats, the cell may identify the incorrect EGFP copy as a template for homology-directed
repair, producing a full-length EGFP sequence. Here, we crossed RaDR mice with animals
expressing different levels of a BER glycosylase to explore the relationship between BER
intermediates and HR mutations.
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Aag is a monofunctional DNA glycosylase that recognizes and excises a variety of
substrates. This enzyme can remove 3-meA, 7-meG, 3-meG, Hx and gA, leaving an abasic site
[12]. AagTg animals, which express increased levels of Aag, were created by the Samson
laboratory, first reported in 2009 [13] and characterized in 2013 [14]. These animals were
generated by pronuclear injection of mouse Aag cDNA under a CMV promoter, and were found
to express Aag -2-9 fold higher than AagWT across tissues.
Previously, the Engelward laboratory has observed that knockout of Aag reduces the
frequency of sequence rearrangement mutations, likely due to fewer BER intermediates being
present at any given time [15]. Further supporting a model whereby BER intermediates promotc
HR, treating wild type animals with MNU (which creates Aag substrates) caused an increase in
sequence rearrangements, but MNU in Aag null animals did not significantly increase these
mutations. Thus, we hypothesized that animals expressing an elevated level of Aag (AagTg)
would accumulate more RaDR mutations over time than wild type.
4.3 Materials and Methods
4.3.1 RaDR;AagTg animals
RaDR'I and RaDR/+ ;AagTg mice were bred by crossing female 129 RaDRR/R mice with male
129 AagTg mice (a generous gift from L.D. Samson). These mice were housed in a barrier
facility free of known murine Helicobacter species, viruses, Salmonella species, Citrobacter
rodentium, ecto- and endoparasites. Animals were aged with no manipulation for 6 months, at
which time they were euthanized by CO 2 according to AVMA guidelines and necropsied with
standard procedures. Samples collected and analyzed immediately included: RaDR imaging of
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pancreas, liver, colon, and mammary tissues, and RaDR flow cytometry of brain, heart, lung,
kidney, thymus, and spleen tissues.
4.3.2 RaDR Necropsy and Tissue Imaging
Animals were euthanized with CO 2 according to AVMA guidelines. Tissues were excised and
held on ice in tubes containing PBS (mammary, brain, heart, lung, kidney, thymus, spleen) or
PBS with 0.0 1% trypsin inhibitor (T9008 Sigma-Aldrich or P-1540 Westnet Inc) (pancreas,
liver, colon) until use. Intestines were cut open on one side and the lumen was rinsed of fecal
matter before placing in PBS + trypsin inhibitor. Mammary, pancreas, liver and colon tissues
were compressed to 0.5 mm between coverslips and imaged for EGFP under the Ix objective
with the FITC filter of a Nikon 80i fluorescent microscope.
4.3.3 RaDR Image Analysis
RaDR images can be analyzed for the number of de novo recombination events by quantifying
individual fluorescent foci, or for total burden of recombinant cells by measuring the fluorescent
area of the tissue. Both metrics are normalized to tissue area, measured in ImageJ. To quantify
fluorescent foci, Dushan Wadduwage of Peter So's laboratory designed MATLAB-based
programs that use gradient and intensity features of the image to distinguish individual foci
(manuscript under review). The program "FociCounter_3.1" was used to enumerate all foci in
pancreas, liver, and mammary tissues, and the program "17.03.27_Crypt counter with GUI" was
utilized to enumerate converted colonic crypts. The crypt counting program is trained to
recognize crypt foci based on 3-4 researcher-annotated images from the data set, then the
program is able to apply those parameters to identify crypt foci in other images. To quantify the
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fluorescent area within the tissue, conservative intensity thresholds were set in ImageJ such that
background and artifactual fluorescence was excluded, and only brightly fluorescent pixels
would be measured. After marking the outline of the tissue, the area of pixels above the threshold
intensity were measured as well as the total tissue area.
4.3.4 RaDR Flow Cytometry
Tissues analyzed by flow cytometry were processed after imaging was completed. Briefly,
tissues were placed in 5 mL of 2 mg/ml collagenase type V (C9263, Sigma) in HBSS (Life
Technologies) in a GentleMACS C tube and mechanically dissociated with the GentleMACS
tissue grinder (Miltenyi Biotec). After mechanical disaggregation, the tissues were placed in a
37C incubator for 40 minutes to allow collagenase to degrade connective tissue. Cell suspensions
were then triterated 10-15 times and passed through a 70 micron cell strainer into 10 mL of cold
media (DMEM + 10% FBS + pen/strep) to halt collagenase digestion. The samples were then
centrifuged at 180 x g for 10 minutes and supernatant was discarded. The cell pellet was
resuspended in 350-500 uL of Opti-MEM reduced serum media (ThermoFisher Scientific) and
held on ice until analyzed. The samples were analyzed by a FACScan or FACS Calibur flow
cytometer for green fluorescence (530 nm) and red (585 nm) to account for autofluorescence.
4.3.5 Abasic Site Quantification
Abasic sites were quantified from colon DNA with the Dojindo AP-site counting kit (Dojindo
Molecular Technologies, Inc, Rockville, MD). Briefly, DNA was extracted from snap-frozen
colon tissue by homogenization and extraction with the Roche DNA Isolation kit for cells and
tissues (Roche Diagnostics Corporation, Indianapolis, IN). A portion of the extracted DNA was
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diluted to 100 ptg/mL and abasic sites labeled with a biotin-tagged aldehyde reactive probe.
Labeled DNA was bound to a clear 96-well plate, incubated with HRP-conjugated streptavidin,
and treated with peroxidase to permit colorimetric detection by optical density at 650 nm.
4.3.6 Statistical Analyses
RaDR foci were quantified as the number of foci per square centimeter of area (foci/cm 2), and
RaDR flow cytometry measurements were given as % fluorescent* 106. Due to the fact that the
distribution of EGFP-positive cells in RaDR mice is non-normal across tissues and among
individuals, RaDR data sets were compared by Mann-Whitney U-test using GraphPad Prism 5.
Due to the wide spread of data, some tissues were analyzed a second time after removing outliers
(outliers defined as x < QI - (1.5*[Q3-Q 1]) or x > Q3 + (1.5*[Q3-Ql]), where QI and Q3
represent the first and third quartiles of data in the set, respectively).
4.4 Results
4.4.1 AagTg animals accumulate fewer mutations compared to AagWT in the pancreas,
colon, spleen, and lung
We measured recombinant EGFP+ cells in ten tissue types by imaging (colon, pancreas, liver,
mammary) or flow cytometry (brain, heart, lung, kidney, thymus, spleen). De novo mutations
were quantified by automated image analysis in pancreas, liver and mammary tissue. Colon
images were similarly analyzed, both for all foci as well as for converted crypts.
There were statistically fewer mutation foci in the pancreata and colon crypts of AagTg
animals (Fig 4-1A), and a lower overall proportion of mutated cells in AagTg spleens (Fig 4-1B).
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Following removal of statistical outliers (see Materials and Methods), AagTg animals were also
found to have a lower proportion of mutated cells in the lung (Fig 4-1 B).
4.4.2 AagTg animals have sex-dependent differences in tissue-specific accumulation of
mutations
Several studies using AagTg animals have revealed sex-dependent differences in susceptibility to
toxicity from DNA methylating agents in the kidney [16], cerebellum [17] and retina
(unpublished data). Therefore, we were interested to know whether the accumulation of sequence
rearrangement mutations varied by sex of the animal. RaDR foci and flow cytometry data were
separated by sex and re-analyzed for significance.
Interestingly, female AagTg animals only showed a significant decrease in mutation
accumulation compared to AagWT in the pancreas (Fig 4-2A). In all other tissues, female
AagWT and AagTg animals showed similar frequencies or proportions of mutations. In fact, the
significant difference in colon crypt and spleen mutations between AagWT and AagTg in sex-
pooled data is derived almost entirely from male animals, as the data spread between females
was nearly identical in these tissues (Fig 4-2B, C).
By separating data by animal sex, we also discovered that AagTg males develop
significantly lower proportions of mutant cells in the heart (Fig 4-2D) as well as the kidney (after
removing outliers - see Materials and Methods) (Fig 4-2E), a distinction that was not visible in
the sex-pooled data. In both these tissues, AagWT males accumulate a larger proportion of
mutant cells compared to both AagTg males as well as AagWT females.
Data for tissue types that did not display statistical differences are presented in Figure 4-
3.
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4.4.3 Frequency of mutations does not necessarily correlate with frequency of abasic sites
The observed decrease in RaDR mutations in AagTg animals was unexpected, as we had
previously shown that BER intermediates promote HR and anticipated that AagTg animals
would have more BER intermediates than AagWT. Since our hypothesis was dependent on the
assumption that AagTg animals would have more BER intermediates, we first aimed to
determine whether this assumption was correct. The Aag glycosylase produces abasic sites, and
other BER intermediates are downstream of glycosylase activity, so we utilized a kit to quantify
abasic sites in AagWT and AagTg colon tissue, three animals of each sex. We did not observe
significant differences in abasic sites between AagWT and AagTg nor between male and female
(Fig 4-4). However, this data is from a small sample size, and so we do not posit firm
conclusions relating abasic sites to mutations.
4.4.4 Correlation analysis suggests tissue mutation frequency may correlate within an
animal, but mutant accumulation does not
Given the wide spread of mutation data between individual animals, we aimed to clarify whether
animals that have a large number of recombinant cells in one tissue are also likely to have high
levels of mutants cells across other tissues. In collaboration with Duanduan Ma of MIT's
BioMicro Center, we calculated Spearmann correlation coefficients for all tissues. Correlation
coefficients are listed in Figure 4-5A, and p-values for each coefficient are listed in Figure 4-5B.
Interestingly, most tissues analyzed for mutation frequency (i.e., foci) correlated significantly,
whereas most tissues analyzed for overall mutant proportion (i.e., flow cytometry) did not
correlate. Two tissues were exceptions, however: mammary foci did not correlate with other
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mutation frequencies, and the mutant proportion of the spleen correlated weakly with pancreas
and colon crypt foci.
4.5 Discussion
In this study, we aimed to determine whether increased expression of the Aag glycosylase affects
the production of sequence rearrangement mutations. Previous studies have shown that Aago-
animals develop fewer HR-driven mutations, likely due to the presence of fewer BER
intermediates. Therefore, we hypothesized that animals expressing elevated levels of Aag would
accumulate more sequence rearrangement (RaDR) mutations from the increase in BER
intermediates. Surprisingly, counter to our initial hypothesis, AagTg animals accumulated fewer
sequence rearrangement mutations overall. The decrease in RaDR mutations in AagTg animals
was statistically significant in the pancreas, colon crypts, spleen, and lung after removal of
outliers. Separating data by sex of the animal further revealed that AagTg males accumulate
fewer mutations than AagWT males in the colon, heart, kidney and spleen, whereas females only
appear to have an Aag-dependent decrease in mutations in the pancreas.
Since our initial hypothesis predicted that AagTg animals would have more mutations
due to more BER intermediates, we sought to determine whether there was a difference in BER
intermediates. We measured abasic sites in the colons of AagWT and AagTg animals, three
animals of each sex. We did not observe a significant difference in abasic sites for either
genotype or sex, suggesting that AagTg animals do not necessarily have an imbalance in the
BER pathway. Previous studies reported that AagTg animals have higher ParpI activity
compared to AagWT [16], suggesting that increased expression of Aag causes upregulation of
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downstream factors as well. We hypothesize that since our animals were not treated with a DNA
damaging agent, downstream steps of the BER pathway were able to keep up with Aag activity,
resulting in improved efficiency and an overall decrease in mutations. Thus, since the BER
pathway was not stressed, efficient repair in both AagTg and AagWT animals resulted in
similarly low levels of abasic sites.
Importantly, other studies of sequence rearrangement mutations in AagWT and Aag null
animals analyzed mutations following alkylation DNA damage [ 15]. Furthermore, AagTg
animals are more sensitive than AagWT to toxicity by alkylating agents [14, 16, 17]. Thus, we
predict that treatment with an alkylating agent could reverse the trend observed here, and
RaDR;AagTg animals would accumulate more recombinant cells than RaDR;AagWT. This work
enables many exciting studies on the Aag-dependent accumulation of recombinant cells
following exposures.
The difference in recombinant cell accumulation between male and female kidneys
particularly interesting because previous studies with AagTg animals have shown that estrogen is
protective against alkylation-induced nephrotoxicity [16]. Our finding that AagWT females
accumulate fewer mutated kidney cells than AagWT males is consistent with males being more
susceptible to renal damage in a variety of model systems [16, 18-20].
The sex-dependent differences in mutation accumulation indicate that there may be sex-
related differences in AagTg expression. The initial characterization of Aag activity across
tissues in the AagTg animal did not separate based on sex of the animal. Based on the sex-linked
differences in mutation accumulation, it will be of great interest to characterize Aag activity
across tissues of both male and female animals. This is especially important for further studies
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using these animals, as sex-dependent variations in Aag activity may drive other sex-dependent
phenotypes in AagTg mice.
4.6 Conclusions
In this study, we assessed the baseline accumulation of RaDR mutations in AagTg and AagWT
mice after six months of age in 10 tissues. Overall, in all cases where there was a difference
between AagTg and AagWT, the AagTg animals had developed fewer mutations. Separating
data by sex revealed that the differences between AagTg and AagWT mutations is most
pronounced in male animals' tissues, whereas AagTg females only had fewer mutations than
AagWT in the pancreas. Further studies on these animals will illustrate the source of these Aag-
dependent and sex-dependent differences in mutation accumulation. In particular, the activity of
Aag should be measured across tissues of male and female AagWT and AagTg animals to clarify
results of this and other studies [14, 17]. We also anticipate that measuring RaDR mutations in
AagTg, AagWT and Aag null animals following treatment with a DNA-damaging agent will
provide a clearer, more complete paradigm linking BER intermediates to HR-derived mutations.
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Chapter 5
Conclusions and Future Work
The experiments comprising this thesis have revealed a number of notable insights
regarding when and how mutations develop. We focused on intestinal inflammation since the
relationship between colonic inflammation and cancer is well established and many models exist
for studying different aspects of colon carcinogenesis. In addition to uncovering mutation
patterns arising from inflammation and DNA damage in the intestine, we also demonstrated the
utility of the RaDR mouse for detecting mutations in unexpected "off-target" tissues, providing a
more comprehensive view of mutagenicity in whole organisms.
First, we studied the impact of inflammation on the promotion stage of cancer using the
ApCMi" + mouse, which contain a cancer-initiating mutation in Apc and spontaneously develop
intestinal tumors. By blocking inflammation with anti-TNF, we decreased tumor multiplicity as
well as overall mutant burden. By exacerbating inflammation with DSS, we increased both
tumors and overall mutant burden. In both cases, converted crypt foci were unchanged relative to
control. Together, these studies show that inflammation does not contribute significantly to de
novo sequence rearrangement mutations in colonic crypt stem cells, but it does increase the
overall burden of mutant cells through elevated proliferation. The inflammation-associated
increase in proliferation correlates with tumor incidence because every division provides cells
another opportunity to acquire more potentially oncogenic mutations.
We also incorporated the variable of DNA damage into our studies of inflammation. Our
first experiment combined both inflammation and DNA damage in one treatment by infecting
Rag2-'- mice with Helicobacter hepaticus, a murine pathogen that causes DNA double strand
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breaks (DSBs) with its cytolethal distending toxin (CDT) [1]. Initially, we were surprised to
discover that this pathogenic infection did not increase mutations, and may have even decreased
mutation frequency. Subsequent experiments treating Apcmi/+ mice with AOM also showed a
decrease in recombinant colon crypts. These similar patterns of decreased crypt foci under
conditions of DNA damage, either DSBs from a bacterial toxin or methylation from a chemical
carcinogen, lend support to Cairns' immortal strand hypothesis, which suggests that DNA
damage induced in a somatic stem cell will cause the cell to preferentially undergo apoptosis
rather than risk mutating [2]. Importantly, the immortal strand hypothesis also suggests that
when a stem cell dies it is replaced by a dedifferentiated daughter cell [3], but our observations
do not support that theory because if a RaDR mutant crypt stem cell were to die, all of its
daughter cells necessarily also have the RaDR mutation and the frequency of recombinant crypts
would be unchanged. More work is necessary to determine the mechanism of replacing crypt
stem cells after apoptosis.
An unexpected and intriguing finding in the work described here is that of increased
recombinant foci in Rag2~ pancreata. Rag2 is thought to be a lymphoid-specific gene [4, 5] and
has not been detected in the mouse pancreas [6], so the relationship between Rag2 and
recombination in the pancreas is as yet inscrutable. We are preparing to collaborate with Dr. Bert
van de Kooij of the Yaffe laboratory to query DSB repair in Rag2J- cells. Given that Rag2 is
considered lymphoid-specific, any relationship between Rag2 and pancreatic DSB repair will be
a novel finding.
Finally, the pattern of fewer recombinant cells in AagTg animals will provide the basis
for many interesting studies regarding balance between Base Excision Repair (BER) and
homologous recombination (HR). We had previously observed that Aag'- animals accumulate
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fewer recombinant foci compared to WT following treatment with the DNA alkylating agent
methylnitrosourea (MNU) [7], and from this we formed our hypothesis that AagTg animals
would have more BER intermediates and therefore more recombination events. Here, we show
that unchallenged AagTg animals accumulate fewer sequence rearrangement mutations than WT,
possibly by more efficient resolution of BER intermediates. This, along with the observation of
sex-dependence in mutant cell accumulation, will provide important foundations for upcoming
experiments treating RaDR;Aag-, RaDR;AagWT and RaDR;AagTg with the environmental
toxicant N-nitrosodimethylamine, a DNA methylating agent.
The work comprising this thesis has provided numerous novel insights to mutagenic
recombination and will form the basis for many exciting further studies. Inflammation appears to
increase the overall burden of mutant cells by increased proliferation, but we have not separated
the variables of inflammation and proliferation to verify whether proliferation is the key to
increasing mutant burden. DNA damage decreases the frequency of recombinant crypts, but
more work is required to determine what exactly happens to colon stem cells following DNA
damage. Studies into the relationship between Rag2 and pancreas DSB repair will provide novel
insights to Rag2 activity and lineage specificity. Finally, the tissue- and sex-dependent patterns
of decreased RaDR mutant cells in AagTg animals highlights the importance of further
characterizing Aag activity across tissues and between sexes in preparation for treatment studies
in Aag-l-, AagWT and AagTg animals. This thesis presents numerous exciting findings about how
organisms develop and accumulate mutations, and provides many opportunities for further
discovery.
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